



(11) **EP 2 046 378 B9**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Description Paragraph(s) 33, 38, 56

(51) Int Cl.:
A61K 39/102 (2006.01) **A61P 31/04** (2006.01)

(86) International application number:
PCT/IB2007/002875

(48) Corrigendum issued on:
23.02.2011 Bulletin 2011/08

(87) International publication number:
WO 2008/004128 (10.01.2008 Gazette 2008/02)

(45) Date of publication and mention
of the grant of the patent:
10.03.2010 Bulletin 2010/10

(21) Application number: **07804998.8**

(22) Date of filing: **25.06.2007**

(54) **USE OF BACTERIAL POLYSACCHARIDES FOR BIOFILM INHIBITION**

VERWENDUNG BAKTERIELLER POLYSACCHARIDE FÜR BIOFILMHemmung

UTILISATION DE POLYSACCHARIDES BACTÉRIENS POUR EMPÊCHER LA FORMATION D'UN
FILM BIOLOGIQUE

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE
SI SK TR**

(30) Priority: **30.06.2006 EP 06291080**

(43) Date of publication of application:
15.04.2009 Bulletin 2009/16

(73) Proprietors:
• **Institut Pasteur**
75015 Paris (FR)
• **Centre National de la Recherche Scientifique**
75016 Paris (FR)

(72) Inventors:
• **GHIGO, Jean-Marc**
92260 Fontenay aux Roses (FR)
• **VALLE, Jaione**
Zizur Mayor (ES)

• **DA RE, Sandra**
87100 Limoges (FR)

(74) Representative: **Marcadé, Véronique et al**
Cabinet Ores
36, rue de St Pétersbourg
75008 Paris (FR)

(56) References cited:
EP-A2- 0 208 375 WO-A-2006/046143
US-A1- 2003 165 870

• **WELCH R A ET AL: "Extensive mosaic structure
revealed by the complete genome sequence of
uropathogenic Escherichia coli" PROCEEDINGS
OF THE NATIONAL ACADEMY OF SCIENCES OF
USA, NATIONAL ACADEMY OF SCIENCE,
WASHINGTON, DC, US, vol. 99, no. 26, 24
December 2002 (2002-12-24), pages 17020-17024,
XP002283177 ISSN: 0027-8424**

EP 2 046 378 B9

Description

[0001] The present invention pertains to the field of biofilm prevention. More particularly, the invention provides novel components which can prevent and/or inhibit bacterial biofilm formation on various surfaces.

[0002] A biofilm is an accumulation of microorganisms embedded in a polysaccharide matrix and adherent to a biological or a non-biotic surface. Diverse microorganisms (bacteria, fungi, and/or protozoa, with associated bacteriophages and other viruses) can be found in these biofilms. Biofilms are ubiquitous in nature and are commonly found in a wide range of environments, including domestic and industrial water systems.

[0003] Biofilms are also etiologic agents for a number of disease states in mammals. Examples include infections of the oral soft tissues, teeth, middle ear, gastrointestinal tract, urogenital tract, airway/lung tissue, peritoneal membrane and eye. Biofilms also develop on medical indwelling devices, such as dental implants, urinary tract prostheses, peritoneal dialysis catheters, indwelling catheters for hemodialysis and for chronic administration of chemotherapeutic agents (Hickman catheters), cardiac implants such as pacemakers, prosthetic heart valves, ventricular assist devices (VAD), synthetic vascular grafts and stents, prostheses, internal fixation devices, percutaneous sutures, and tracheal and ventilator tubing.

[0004] Biofilm development in industrial devices such as water systems or agri-food plants also raises safety problems.

[0005] Planktonic bacteria (*i.e.*, single-celled bacteria suspended in liquid media) are usually used as models for research and antibiotics design. However, bacteria in biofilms are far more resistant to antibiotics than their planktonic counterparts, and less accessible to the immune system. Moreover, conjugation occurs at a greater rate between cells in biofilms than between planktonic cells. This increased opportunity for gene transfer among bacteria is important, since bacteria resistant to antimicrobials or chemical biocides can transfer the genes for resistance to neighboring susceptible bacteria. Gene transfer can also convert a previous avirulent commensal organism into a highly virulent pathogen.

[0006] Biofilm formation is not limited to the attachment of bacteria to a surface. Indeed, when growing in depth, biofilm bacteria interact more between each other than with the actual physical substratum on which the biofilm initially developed. In a biofilm, bacteria can communicate through chemical signalling mechanisms, so that the community undergoes phenotypic changes when a minimum density (the quorum) is reached in the biofilm. This phenomenon, called "quorum sensing", can be responsible for the expression of virulence factors.

[0007] Besides *E. coli* biofilm-related polysaccharides such as colanic acid polymer, cellulose and (1-6) β -N-acetylglucosamine, *E. coli* isolates also produce two serotype-specific surface polysaccharides: the lipopolysaccharide (LPS) O antigen and capsular polysaccharide K antigen. These two classes of surface exposed polysaccharidic polymers have been shown to play indirect roles in biofilms by shielding of bacterial surface adhesin (Schembri et al., 2004).

[0008] The strategies described to date for preventing and/or disrupting biofilms are mainly based on quorum sensing inhibitors (Schachter, 2003).

[0009] The present invention provides a novel strategy for inhibiting biofilm formation, since the inventors have demonstrated, using *in vitro* mixed-species bacterial biofilm, that some bacteria release in the culture supernatant a soluble group II capsular polysaccharide that prevents biofilm formation by a wide range of Gram-negative and Gram-positive bacteria. As described in the experimental part below, these capsule components induce physico-chemical alterations of surface, leading to a reduction of cell-surface and cell-cell contacts that limits both initial adhesion and bacterial biofilm development.

[0010] A first object of the present invention is hence the use of a soluble group II-like capsular polysaccharide from a bacterial strain, for the preparation of a composition which prevents or inhibits adhesion of micro-organisms and/or biofilm development, in particular bacterial adhesion and/or bacterial biofilm development. In what follows, the term "polysaccharide", although used in the singular, can designate a mixture of different polysaccharides. The capsular polysaccharides produced by the bacteria are indeed of various sizes. In fact, *E. coli* capsules, which constitute the outermost protective layer of the cell surface, are classified into four groups based on genetic and biosynthetic criteria. Group II capsule is one of the 4 capsular types described in *E. coli*, and is constituted of high molecular weight and charged polysaccharidic polymers produced by most uropathogenic *Escherichia coli* (UPEC) and other extra-intestinal *E. coli*. Group II capsule displays a conserved modular genetic organization characterized by 3 functional regions. Region I (kpsFEDCUS) and region 3 (kpsMT) are conserved in all group II capsulated bacteria and encode proteins required for ABC-dependent export. Region 2 encodes a diversity of polysaccharidic structural components such as K1, K2 (CFT073), K5 and K96 capsular serotypes (Whitfield, 2006; Whitfield and Roberts, 1999). Group II-like capsules have also been described in *Hemophilus influenzae* and in *Neisseria meningitidis* (Roberts, 1996).

[0011] In a preferred embodiment of the invention, a soluble group II-like capsular polysaccharide is obtained in the supernatant of a culture of bacteria selected amongst *Escherichia coli*, *Hemophilus influenzae* and *Neisseria meningitidis*. However, in the present text, the phrase "group II-like capsular polysaccharides" can designate capsular polysaccharides which are produced by other bacteria, provided they retain the anti-biofilm properties observed for the capsular polysaccharides produced by the above-mentioned strains. For example, capsular polysaccharides produced by the strain 47 of the ECOR collection (Ochman and Selander, 1984) are herein considered as a "group II-like capsular polysaccharide",

although this strain apparently produces a hybrid group II/group III capsule.

[0012] The present invention can be performed with polysaccharides having different purification levels. For example, the crude supernatant of a bacterial culture (separated from the bacteria by filter-sterilizing or centrifugation) can be used according to the invention as a composition comprising soluble group II-like capsular polysaccharides. However, in order to increase the anti-biofilm activity of the composition, as well as its safety, the soluble group II-like capsular polysaccharide can be obtained as a purified fraction. Three levels of purification are described in the experimental part below, as non-limitative examples. Alternatively, a composition according to the invention can be obtained directly from the bacterial culture, for example after lysis of the bacteria.

[0013] Another object of the present invention is a composition for inhibiting bacterial adhesion and/or bacterial biofilm development, which comprises a soluble group II-like capsular polysaccharide from a bacterial strain. Such a composition can comprise polysaccharides having different purification levels. In a preferred embodiment, such a composition comprises a purified fraction of the supernatant of a culture of bacteria selected amongst *E. coli*, *H. influenzae* and *N. meningitidis*, comprising soluble group II-like capsular polysaccharides.

[0014] The present invention also relates to a process for purifying an anti-biofilm group II-like capsular polysaccharide from a bacterial strain, comprising the following steps:

- (i) separating the supernatant of a culture of a bacterial strain expressing a group II-like capsule from the bacterial cells,
- (ii) precipitating the polysaccharides present in the obtained supernatant, and
- (iii) optionally, resuspending the precipitate.

[0015] The above process is preferably performed with a bacterial strain selected amongst *E. coli*, *H. influenzae* and *N. meningitidis*, more preferably with an uropathogenic *E. coli*.

[0016] In this process, step (i) can be carried out by centrifuging and/or filter-sterilizing the bacterial culture, in order to eliminate the bacterial cells. For example, in industrial processes, tangential filtration can be performed without any preliminary centrifugation. Tangential filtration can be performed continuously.

[0017] The skilled artisan can use any precipitation process known in the art to perform the second step of the above-described process. For example, the precipitation in step (ii) can be performed with three volumes of ethanol for one volume of supernatant.

[0018] In an advantageous variant of the process according to the invention, the precipitate obtained in step (ii) is first resuspended in water, dialyzed against deionised water, and then lyophilized before step (iii).

[0019] The resuspension in step (iii) can be done in water or in any buffer suitable for the intended use. An example of buffer which can be used is TrisHCl 20 mM, pH 7.5, with 25% propanol-1.

[0020] At the end of step (iii), the anti-biofilm polysaccharides are obtained as a semi-purified product, which can be used as such according to the invention, especially in applications which do not need medical-grade products.

[0021] In order to further purify the polysaccharides, the purification process can comprise an additional step (iv) of purification by chromatography, especially ion exchange chromatography, for example using a DEAE-Sepharose column. In this embodiment of the invention, an optional centrifugation step can be performed between step (iii) and step (iv), to discard the insoluble fraction.

[0022] The skilled artisan can choose any appropriate buffer for performing step (iv). An example of buffer which can be used is TrisHCl 20 mM, pH 7.5, with 25% propanol-1. According to an advantageous embodiment of the process, the precipitate is resuspended in TrisHCl 20 mM, pH 7.5, with 25% propanol-1 in step (iii), and the column used in step (iv) is equilibrated with the same buffer.

[0023] When performing a step of purification by ion-exchange chromatography, the group II-like capsular polysaccharides can be eluted using a salt gradient, for example a NaCl gradient. In an efficient embodiment of the process, described in the experimental part, the group II-like capsular polysaccharides are eluted with 300 mM NaCl in TrisHCl 20 mM, pH 7.5, 25% propanol-1.

[0024] Of course, the soluble group II-like capsular polysaccharides obtained through a process as above-described can be used, according to the invention, for the preparation of a composition which prevents or inhibits bacterial adhesion and/or bacterial biofilm development. An anti-biofilm composition comprising such purified polysaccharides is also part of the present invention.

[0025] In a particular embodiment, the composition of the present invention is formulated for preventive or therapeutic administration to a subject in need thereof. Non-limitative examples of compositions according to this aspect of the invention are oral solutions, solutions for infusion into the ear, collyrium, toothpaste or therapeutic dentifrice, etc. These compositions can be used, for example, to prevent the (re)-colonization of the gut, the lung, the ear, the sinus or any other organ or cavity, by pathogenic bacteria.

[0026] In another embodiment, the composition according to the invention is a liquid or a paste, for example a paint, which can be applied on any kind surfaces in order to prevent biofilm formation on these surfaces.

[0027] Another aspect of the present invention is an anti-biofilm coating, comprising a group II-like capsular polysac-

charide from a bacterial strain. In such a coating, the group II-like capsular polysaccharide can have different purification levels, as described above. In a preferred embodiment of the coating according to the invention, the group II-like capsular polysaccharide is from a bacterial strain selected amongst *Escherichia coli*, *Hemophilus influenzae* and *Neisseria meningitidis*. This coating can be obtained, for example, by application of a composition as above-described. It can also be in the form of sheets which can be applied on any kind of device on which biofilm formation must be avoided.

[0028] Accordingly, a medical or industrial device, which is at least partly coated with an anti-biofilm coating comprising a group II-like capsular polysaccharide from a bacterial strain, is also part of the present invention. Such an object can be obtained, for example, by dipping part of the device or the whole device, into a liquid composition as described above. The skilled artisan can choose the incubation duration, depending on the material, the concentration of the composition in group II-like capsular polysaccharide, the intended use, and the like. Typically, said incubation can last from 10 seconds to 30 minutes. Short incubations (≤ 1 to 5 minutes) are usually sufficient. If necessary, the coated device can then be sterilized by a variety of treatments, without damaging the coating. For example, it can be intensively washed and/or autoclaved. Any kind of device made of glass, pyrex, PVC, polycarbonate, polypropylene and the like, can advantageously be coated according to this aspect of the invention.

[0029] Non-limitative medical devices which can advantageously be coated according to this aspect of the invention are scalpels, burs and other non-disposable surgery and/or dentistry tools, and indwelling devices, such as dental implants, urinary tract prostheses, peritoneal dialysis catheters, indwelling catheters for hemodialysis and for chronic administration of chemotherapeutic agents (Hickman catheters), cardiac implants such as pacemakers, prosthetic heart valves, ventricular assist devices (VAD), synthetic vascular grafts and stents, prostheses, internal fixation devices, percutaneous sutures, and tracheal and ventilator tubing.

[0030] Non-limitative examples of industrial devices which can advantageously be coated according to this aspect of the invention are plumbing materials, such as pipes, tubes, valves and the like, air-cooled towers, warm water systems, coolant circuits of nuclear power plant, especially secondary and tertiary circuits, agri-food materials, such as silos, fermenters, colanders, etc., furniture elements such as lab tables, counter tops and the like, especially for clean rooms, etc.

[0031] The invention is further illustrated by the following figures and examples.

FIGURE LEGENDS

[0032]

Figure 1: Biofilm inhibitory effect of CFT073. **A**, Biofilm formation of MG1655 F' in microfermentors inoculated with 1 or 10 OD_{600nm} equivalent of KS272 (grey) or CFT073 (black) cells. MG1655F' biofilm alone ($\emptyset$, white). Results are average of 6 replicates $\pm$ s.d. $P < 0.001$ compared with MG1655F' biofilm. **B**, Microtiter plate MG1655F' biofilm alone ($\emptyset$), or in the presence of KS272 or CFT073 supernatant, (S.KS272 and S.CFT073, respectively). **C**, MG1655F' biofilm in microfermentors perfused with medium without supernatant ($\emptyset$) or with S.KS272 or S.CFT073. **D**, Growth curves of MG1655F' alone ($\emptyset$) or with S.KS272 or S.CFT073. **E**, MG1655F' cell viability alone ($\emptyset$) or with S.KS272 or S.CFT073 visualized with BacLight staining. **F**, Qualitative analysis of the biofilm formation in microtiter plate by different bacteria in the presence of CFT073 supernatant (S. CFT).

Figure 2: Effect of CFT073 supernatant on Gram-positive and Gram-negative bacterial biofilm formation.

A, Quantification of the microtiter plate biofilm formation of different bacteria, alone ($\emptyset$), with KS272 (S.KS) or CFT073 (S.CFT) supernatant. Levels of crystal violet retained were measured spectrophotometrically (OD_{570nm}). **B**, Quantification of biofilm formed by several pathogenic bacteria in microfermentors using media not supplemented ($\emptyset$), or supplemented with S.CFT or S.KS. Error bars represent standard deviation of two independent experiments. **C**, Effect of CFT073 supernatant (S.CFT073) in mix biofilms of *E. coli* (MG1655F') with *P. aeruginosa* (PAK), *K. pneumoniae* (KP21), *S. epidermidis* (O-47), *S. aureus* (15981) and *S. epidermidis* (O-47) with *S. aureus* (15981) and *E. faecalis* (54). Supernatant of *E. coli* CFT073 Δ kpsD strain (S. Δ kpsD) that do not secrete any group II capsule is used as negative control. **D**, Qualitative analysis of biofilm formation of *S. aureus* and *P. aeruginosa*, in a microfermentor using media not supplemented, or supplemented with CFT073 supernatant.

Figure 3: Relationship between capsule production and anti-biofilm activity of the CFT073 supernatant. **A**,

Genetic organization of the CFT073 capsule R1, R2 and R3 regions. Genes with transposon insertions are marked with an asterisk. **B**, Biofilm formation of MG1655F' cultivated in the presence of the capsule mutant supernatants. **C**, Hexose levels in the supernatants. *kpsF*, *kpsU*, *c3692* and *c3693* correspond to mutants that do not impair capsule production. **D**, Stationary phase CFT073 or CFT073 Δ bacterial cell capsules stained with ferritin and examined by transmission electron microscopy (X100000; bar = 0,2 μ m) (left panel); 125 and 105 cells were observed respectively. Stained CFT073 capsule is indicated by an arrow. On the right panel: scanning electron micrographs of stationary-phase CFT073 or CFT073 Δ kpsD (X50,000; bar = 0.5 μ m); 45 and 37 cells were observed respectively.

Figure 4. Correlation between anti-biofilm activity and group II capsule. Biofilm formation of *E. coli* MG1655F' and 1091 strains, and of the *S. aureus* 15981 strain cultured with: **(A)** supernatants of *E. coli* exhibiting anti-biofilm

activity (see Table 1) (beside strain 47, all the strains tested produce group 11 capsule) **(B)** supernatants of CFT073, U-9, U-15 strains and their respective *kpsD* mutants. **(C)** Biofilm formation in microfermentor of UPEC strains CFT073, U-9, U-15 (black) and their respective *kpsD* mutants (grey) grown in M63B1glu, and *kpsD* mutants grown in media supplemented with their corresponding wild-type supernatant (white). Biofilms were grown for 36 h at 37°C. Error bars represent standard deviation of the mean. Strains identified by simple numbers correspond to those of the EcoR collection (Ochman and Selander, 1984).

Figure 5. Anti-biofilm effect of *Neisseria meningitidis* supernatant. Quantification of the microtiter plate biofilm formation of MG1655F' in the presence of *S. Neisseria*. OD_{570nm} of the crystal violet dye was determined as described in (O'Toole and Kolter, 1998).

Figure 6: Physico-chemical properties of the CFT073 supernatant. **a**, ζ potential of cationic colloids incubated with the dialyzed supernatants from: CFT073 (CFT), U-9, IHE3034 (IHE), EcoR72 (E-72) (dark grey) and their respective capsule mutants (light grey). ($\emptyset$) correspond to M63B1glu treatment. **b**, Water droplet contact angle on surface incubated with CFT, U-9, IHE, E-72 (dark grey) and the capsule mutants (light grey). **c**, Propidium iodide adsorption onto cationic particles incubated with CFT, U-9, IHE, E-72, FR2 (CFT073 supernatant purified fraction), (dark grey) and their respective capsule mutants (light grey). The extent of the adsorption is given by the fluorescent intensity (>670nm). **d**, Fluorescence microscopy of cationic particles incubated with CFT, S.CFT073 Δ R1 ($\emptyset$ R1), FR2 and not incubated ($\emptyset$). Error bars represent the standard deviation of the mean.

Figure 7: Biofilm inhibition effect of CFT073 supernatant on coated surfaces. Biofilm formation in microfermentors by several bacteria using: untreated glass slides (upper panel), glass slides treated with CFT073 supernatant (middle panel) and glass slides treated with CFT073 Δ *kpsD* supernatant (lower panel).

Figure 8. Impact of the treatment of spatula coated with S.CFT073 supernatant (S.CFT). Biofilm formation in microfermentors by MG1655F' using untreated glass slides and glass slides treated with S.CFT or with boiled S.CFT, and then autoclaved or submitted to intensive wash.

Figure 9: CFT073 supernatant affects cell-cell interaction. **A**, MG1655F' biofilm formation in microfermentors with media supplemented with CFT073 supernatant (S.CFT) at times 0 h, 1 h, 6 h (24 h of culture) and 24 h (48 h of culture). $\emptyset$: no addition of S.CFT. **B**, GFP-tagged MG1655F' inoculated in a flow-cell and monitored by confocal microscopy. CFT073 or KS272 supernatants were supplemented after 3 h of culture and biofilms were grown for 12 h total. **C**, Autoaggregation assay with strains that aggregate via different mechanisms: MG1655F' (F conjugative pilus expression); MG1655*ompR234* (curli overexpression); MG1655 Δ *oxyR* (Ag43 autotransporter adhesin overexpression); 1094 (cellulose production). Cells were diluted to OD₆₀₀ of 2 in 3 ml of M63B1 (triangle), CFT073 supernatant (circle) and Δ *kpsD* supernatant (rectangle).

Figure 10. Anti-biofilm activity of the FR2 fraction. CFT073 supernatant purified fraction (FR2) was added to the MG1655F' culture in concentrations ranging from 0.5 to 500 μ g/ml. Biofilm formation of MG1655F' was visualized after 24 h. Concentration of 50-100 μ g/ml inhibited MG1655 F' biofilm.

Figure 11. Intestinal colonization by CFT073 and CFT073 Δ R1. **a**, Bars represent the standard error of the log₁₀ mean number of CFU per gram of feces; a Mann-Whitney test was used for statistical analysis, the level of statistical significance (*) was set at P values of <0.016. **b**, Colon and caecium colonization by CFT073 (circles) and CFT073 Δ R1 (triangles). DL: Detection limit.

Figure 12. Effect of growth phase and quorum-sensing in the anti-biofilm properties of CFT073 supernatant. Biofilm formation of MG1655F' in microtiter plate in presence of supernatants purified from cells in exponential phase, stationary phase and Δ *luxS* mutant. 10¹⁰ cells in exponential phase (OD_{600nm}=0.4) and in stationary phase (OD_{600nm}=2) were centrifuged and supernatants were precipitated with 3 volumes of ethanol. The supernatant of Δ *luxS* mutant was purified from an overnight culture.

EXAMPLES

Example 1: Methods

Bacterial strains, growth conditions and microscopy analysis

[0033] Bacterial strains are listed in Table 1 below. Gram-negative bacteria were grown at 37°C in M63B1 minimal medium with 0.4% glucose (M63B1glu) or in LB rich medium. Gram-positive bacteria were grown in TSB with 0.25% glucose (TSBglu) at 37°C. The effect of CFT073 supernatant on bacterial growth and viability rate was evaluated using growth curve determination, colony forming unit count on LB plate and BacLight Live/Dead viability stain (Molecular Probes). Ferritin-staining and Scanning Electronic Microscopy was performed as described in (Bahrani-Mougeot et al., 2002). Epifluorescence and transmitted light microscopy were acquired using a Nikon E400 microscope. Autoaggregation assays were performed as described in (Beloin et al., 2006).

TABLE 1: Strains used in this study

	Strains	Relevant characteristics	References
5	<i>E. coli</i> strains		
	CFT073	UPEC group II capsule (K2)	(Mobley et al., 1990)
	MG1655F'	MG1655 F' <i>tet-ΔfraD</i> plasmid	(Ghigo, 2001)
	KS272	Commensal <i>E. coli</i> K-12	(Strauch and Beckwith, 1988)
10	1091	Commensal <i>E. coli</i>	C. Le Bouguenec
	1092	Commensal <i>E. coli</i>	C. Le Bouguenec
	1094	Commensal <i>E. coli</i>	(Da Re and Ghigo, 2006)
	1096	Commensal <i>E. coli</i>	C. Le Bouguenec
	1097	Commensal <i>E. coli</i>	C. Le Bouguenec
15	1102	Commensal <i>E. coli</i>	C. Le Bouguenec
	1103	Commensal <i>E. coli</i>	C. Le Bouguenec
	1110	Commensal <i>E. coli</i>	C. Le Bouguenec
	1125	Commensal <i>E. coli</i>	C. Le Bouguenec
20	1127	Commensal <i>E. coli</i>	C. Le Bouguenec
	U-1	UPEC group II capsule	C. Forestier
	U-2	UPEC group II capsule (K2)	C. Forestier
	U-3	UPEC non-group II capsule	C. Forestier
	U-4	UPEC group II capsule	C. Forestier
25	U-5	UPEC group 11 capsule	C. Forestier
	U-6	UPEC group II capsule (K2)	C. Forestier
	U-7	UPEC non-group II capsule	C. Forestier
	U-8	UPEC group II capsule	C. Forestier
30	U-9	UPEC group 11 capsule	C. Forestier
	U-10	UPEC group II capsule	C. Forestier
	U-11	UPEC non-group II capsule	C. Forestier
	U-12	UPEC group II capsule	C. Forestier
	U-13	UPEC group II capsule	C. Forestier
35	U-14	UPEC non-group 11 capsule	C. Forestier
	U-15	UPEC group II capsule	C. Forestier
	U-16	UPEC group II capsule	C. Forestier
	U-17	UPEC non-group II capsule	C. Forestier
	U-18	UPEC non-group II capsule	C. Forestier
40	U-19	UPEC group II capsule	C. Forestier
	U-20	UPEC group II capsule	C. Forestier
	U-21	UPEC group II capsule (K2)	C. Forestier
	984	Commensal <i>E. coli</i> group II capsule (K1)	M.C. Ploy
45	988	Commensal <i>E. coli</i> group II capsule (K1)	M.C. Ploy
	999	Commensal <i>E. coli</i> group II capsule (K1)	M.C. Ploy
	1007	Commensal <i>E. coli</i> group II capsule (K1)	M.C. Ploy
	1014	Commensal <i>E. coli</i> group II capsule (K1)	M.C. Ploy
	1HE3034	<i>E. coli</i> causing meningitis group II capsule (K1)	(Meier et al., 1996)
50	EcoR strains	<i>E. coli</i> Reference Collection (72 strains)	(Ochman and Selander, 1984)
	Other bacteria		
	15981	<i>S. aureus</i> clinical strain	(Valle et al., 2003)
55	V329	<i>S. aureus</i> bovine mastitis subclinical isolate	(Cucarella et al., 2001)
	O-47	<i>S. epidermidis</i> clinical strain	(Heilmann et al., 1996)
	CH845	<i>S. epidermidis</i> clinical strain BM94314	(Galdbart et al., 2000)

(continued)

	Other bacteria		
5	54	<i>E. faecalis</i> clinical strain	(Toledo-Arana et al., 2001)
	11279	<i>E. faecalis</i> clinical strain	(Toledo-Arana et al., 2001)
	KP21	<i>Klebsiella pneumoniae</i> strain	C. Forestier
	PAK	<i>Pseudomonas aeruginosa</i>	(Vasseur et al., 2005)
	8013	<i>Neisseria meningitidis</i> strain, serogroup C, class 1	(Deghmane et al., 2002)
10	Mutants		
	44H3	CFT073 <i>kpsD</i> :: <i>TnSC189</i>	This study
	25F11	CFT073 <i>kpsD</i> :: <i>TnSC189</i>	This study
	23D5	CFT073 <i>kpsU</i> :: <i>TnSC189</i>	This study
15	16B9	CFT073 <i>kpsU</i> :: <i>TnSC189</i>	This study
	14E12	CFT073 <i>kpsC</i> :: <i>TnSC189</i>	This study
	76H11	CFT073 <i>kpsS</i> :: <i>TnSC189</i>	This study
	30H8	CFT073 <i>kpsM</i> :: <i>TnSC189</i>	This study
20	$\Delta kpsD$	CFT073 <i>kpsD</i> :: <i>km</i>	This study
	$\Delta kpsC$	CFT073 <i>kpsC</i> :: <i>km</i>	This study
	$\Delta kpsU$	CFT073 <i>kpsU</i> :: <i>km</i>	This study
	$\Delta kpsS$	CFT073 <i>kpsD</i> :: <i>km</i>	This study
	$\Delta kpsM$	CFT073 <i>kpsM</i> :: <i>km</i>	This study
25	$\Delta 3692$	CFT073 $\Delta 3692$:: <i>km</i>	This study
	$\Delta 3693$	CFT073 $\Delta 3693$:: <i>km</i>	This study
	$\Delta 3694$	CFT073 $\Delta 3694$:: <i>km</i>	This study
	$\Delta 3695-96$	CFT073 $\Delta 3695\Delta 3696$:: <i>km</i>	This study
30	$\Delta R1$	CFT073 with a deletion from <i>kpsD</i> to <i>kpsS</i>	This study
	$\Delta 2$	CFT073 with a deletion from <i>c3692</i> to <i>c3696</i>	This study
	$\Delta R3$	CFT073 with a deletion from <i>kpsT</i> to <i>kpsM</i>	This study
	U-9 $\Delta kpsD$	U-9 <i>kpsD</i> :: <i>km</i>	This study
	U-15 $\Delta kpsD$	U-15 <i>kpsD</i> :: <i>km</i>	This study
35	IHE3034 $\Delta kpsD$	IHE3034 <i>kpsD</i> :: <i>km</i>	This study
	$\Delta luxS$	CFT073 $\Delta luxS$	This study
	CFT073 <i>gfp</i>	CFT073 λ ATT <i>gfp</i>	This study
	$\Delta R1$ <i>gfp</i>	$\Delta R1$ λ ATT <i>gfp</i>	This study
	$\Delta oxyR$	MG1655 <i>oxyR</i> :: <i>km</i>	(Beloin et al., 2006)
40	<i>ompR234</i>	MG1655 <i>ompR234 malA</i> :: <i>km</i>	(Vidal et al., 1998)

Biofilm formation procedures

- 45 **[0034]** *Microfermentors experiments*: Biofilm was performed as described previously (Ghigo, 2001). *Mixed biofilm cultures*: an 8 hours MG1655F' biofilm formed in the internal microfermentors glass slide was infected with 1 OD_{600nm} equivalent of CFT073-*gfp* overnight culture. After 24 hours of continuous culture in M63B1glu, pictures of the glass slides were taken. Biofilm biomass was estimated by determining the OD_{600nm} of the resuspension of the biofilm formed on the internal glass slide (Ghigo, 2001). *Biofilm inhibition assays*: the incoming medium was mixed in a 1:1 ratio with
- 50 filtered supernatants and brought into the microfermentors at different time after bacteria inoculation (0, 1, 6 or 24 hours). The biofilm was further cultivated for an additional 24 hours before biomass determination. *Analysis of bacterial interaction with treated surfaces*: the glass slides were incubated 1 min with filtered CFT073 supernatant and rinsed once in deionised water prior to inoculation in microfermentors. Biofilm formation on the slide was determined after 24 hours.
- 55 **[0035]** *Microtiter plate experiments*. Static biofilm formation assay were performed in 96-well PVC microtiter plates (Falcon) as described in (O'Toole and Kolter, 1998). *Biofilm inhibition assays*: overnight cultures were adjusted to OD₆₀₀=0.04 before inoculating 100 μ l in 96-well plates in the presence or absence of 50 μ l of supernatant. *Flow-chamber experiments*. Biofilms were performed in M63B1glu at 37°C in 3 x channels flow-cells (1 × 4 × 40 mm). The flow system was assembled and prepared as described in (Christensen et al., 1999). Inocula were prepared as follows: 16-20 hours

old overnight cultures in M63B1glu were harvested and resuspended as normalized dilutions ($OD_{600}=0.005$). 300 μ l were injected into each flow channel. Input medium was mixed in a 1:1 ratio with filtered supernatant. Flow was started 1 h after inoculation at a constant rate of 3 ml h^{-1} using a Watson Marlow 205S peristaltic pump. All Assays were at least performed in triplicate.

Purification of CFT073 or other group II capsulated strain supernatants displaying anti-biofilm activity

[0036] Three levels of purification have been tested:

(i) Filtration (sterilization) of the active supernatants (**S.CFT**, used in all the experiments on microtiter plates or in microfermentors)

- Overnight cultures in M63B1glucose 0.4% were centrifuged for 30 min at 5000 rpm at 4°C and filtered through 0.25 μ m filter to eliminate bacteria.

(ii) Precipitation of polysaccharides contained in active supernatants

- The polysaccharides contained in the filtered supernatant were precipitated with 3 volumes of ethanol, resuspended in deionized water and dialyzed against deionized water in 10 kDa cut-off dialysis cassettes (Pierce biochemical).

(iii) purification of the capsular polysaccharides active fraction (capsular active fraction **FR2**)

- the partially purified supernatant active fraction obtained in step (ii) was lyophilized and resuspended in 80 ml of buffer Tris HCl 20 mM pH 7.5 containing 25% deopropanol-1.
- This resuspension was centrifuged for 10 minutes at 3000 rpm to eliminate the insoluble particles.
- the soluble supernatant was loaded on a DEAE-Sepharose column (30 ml, 2.6 x 6 cm, Amersham) and equilibrated with Tris HCl 20 mM pH 7.5, 25% deopropanol-1 buffer.
- the column was washed with Tris HCl 20 mM pH 7.5, 25% deopropanol-1 buffer at the rate of 20 ml/h.
- After the wash, the column was eluted with a NaCl gradient (0 to 1 M in 400 ml) and the polysaccharide concentration of each eluted fractions (4.5 ml) was tested by the Dubois method (Dubois et al., 1956): 100 μ l of phenol at 5% and 500 μ l of concentrated sulfuric acid followed by vortex agitation and read at 492 nm)
- The positive fractions (about 10 fractions of 4.5 ml) were pooled together and dialyzed against deionized water and lyophilized
- 1 mg of the lyophilysate was resuspended in 1 ml of deionized water

Handling of culture supernatants and polysaccharide analysis

[0037] Overnight cultures in M63B1glu at 37°C were centrifuged 30 minutes at 5000 rpm at 4°C. After filtration of the supernatant with a 0.2 μ m filter, macromolecules were precipitated with 3 volumes of ethanol and dialysed against deionised water using 10kDa cassettes (Pierce). Total amounts of phosphate and neutral sugars were determined by ammonium molybdate/ascorbic acid and phenol/sulfuric acid methods, respectively. Polysaccharide composition was determined by HPLC (ion-exclusion column) and by gas liquid chromatography as in (d'Enfert and Fontaine, 1997; Fontaine et al., 2000). CFT073 supernatant active fraction, FR2, was purified using a DEAE-Sepharose column (Amersham) and eluted with 300 mM NaCl in 25% deopropanol-1, 20 mM TrisHCl pH7.5. Molecular weight of the polymer was estimated by gel filtration chromatography on Superdex-200 (Amersham) using dextran as standard. Polysaccharide degradations were done by total acid hydrolysis (trifluoroacetic acid, 4N, 4H, 100°C) or by aqueous hydrofluoric acid (48% aq. HF, 2 days on water-ice).

Mutagenesis and molecular techniques

[0038] Mariner transposon mutagenesis of *E. coli* CFT073 was performed as described in (Da Re and Ghigo, 2006). The supernatants of 10,000 transposon mutants incubated 24h, in LB at 37°C in 96-well microtiter plates were extracted after centrifugation of the plates 15 min at 10000rpm and their effect on MG1655F' biofilm formation was analysed. Transposon insertion sites were determined as described in (Da Re and Ghigo, 2006). Homology searches were performed using Blast 2.0. Deletion mutants were generated as detailed at <http://www.pasteur.fr/recherche/unites/Ggb/3SPCRprotocol.html>, using primers presented in Table 2.

TABLE 2: Primers used in this study.

	Target gene	Primer name	Sequence	SEQ ID No:
5	Primers used to generate deletion mutants			
	kpsD	KpsD.500-5	gaccagcttgcccttgagaaacg	1
		KpsD.500-3	cttttcagcattacgcgtagg	2
		KpsD.GB.L-5	TGCTCGATGAGTTTTTCTAAGGAGTTGAAatgagcaa	3
10		KpsD.GB.L-3	gattttgagacacaacgtggctttCATcacAAACTCATTGAGCGACA	4
		KpsD.ext-5	ttgcgcttaagttaaccaaaccg	5
		KpsD.ext-3	gctctggcatggactccggttaact	6
	kpsU	KpsU.500-5	atgaacgcagttcagcttatcgcc	7
		KpsU.500-3	ccaaatttcggttgaggattttc	8
15		KpsU.GB.L-5	TGCTCGATGAGTTTTTCTAAcaggaactggctgaaaacgcatga	9
		KpsU.GB.L-3	gattttgagacacaacgtggctttCATTTCAACTCCttacaagacaga	10
		KpsU.ext-5	tgagaacgcgcgataccttaacg	11
		KpsU.ext-3	ctcggcaatcaaactgactcgttg	12
20	kpsC	KpsC.500-5	gaggcagatatcaacattaacc	13
		KpsC.500-3	gttgaaggtttaagttctcaac	14
		KpsC.GB.L-5	TGCTCGATGAGTTTTTCTAAACAATTTTCATAGTTGACTATTAC	15
		KpsC.GB.L-3	gattttgagacacaacgtggctttgagtaaatgccaatcatgcgttttc	16
25		KpsC.ext-5	cgactcacattacgattatgcg	17
		KpsC.ext-3	gaaaatgatttggtggcggtagc	18
	kpsS	KpsS.500-5	agagcaaccttgagtattacg	19
		KpsS.500-3	aaagacaagggatagcttagg	20
30		KpsS.GB.L-5	TGCTCGATGAGTTTTTCTAATTTATTCTAAATTATCAACG	21
		KpsS.GB.L-3	gattttgagacacaacgtggcttCATAAATAATCTGTGTAATAGTCAA	22
		KpsS.ext-5	agcgactggttgaaagcaaactg	23
		KpsS.ext-3	ttcgatgagtcagactattgg	24
35	kpsM	KpsM.500-5	TTACTACGCATAAAATTCATGG	25
		KpsM.500-3	aatgccatgcttaaaccaaagcc	26
		KpsM.GB.L-5	TGCTCGATGAGTTTTTCTAAcaatgctgacatcatgattaagattg	27
		KpsM.GB.L-3	gattttgagacacaacgtggctttcttgccatTTGGTGATGTGATCCT	28
		KpsM.ext-5	TCGCATGCGTTCTGGTTTGAG	29
40		KpsM.ext-3	cacatcacaactcttcaatg	30
	Kps	KpsD.500-5	gaccagcttgcccttgagaaacg	31
		KpsS.500-3	aaagacaagggatagcttagg	32
		KpsD.GB.L-3	gattttgagacacaacgtggctttCATcacAAACTCATTGAGCGACA	33
45		KpsS.GB.L-3	gattttgagacacaacgtggctttCATAAATAATCTGTGTAATAGTCAA	34
		KpsD.ext-5	ttgcgcttaagttaaccaaaccg	35
		KpsS.ext-3	ttcgatgagtcagactattgg	36
	Kps	KpsR2.500-5	atataggagtagggagcgaaac	37
		KpsR2.500-3	ttgagtaaggaatatggcttag	38
50		KpsR2.GB-L5	TGCTCGATGAGTTTTTCTAAGAAATCAGACGAGTTTTTC	39
		KpsR2.GB-L3	gattttgagacacaacgtggctttcataacatACTATGTCCCATGATTATT	40
		KpsR2.ext-5	catgtactcatttcacgtaaag	41
		KpsR2.ext-3	tgctaaaattgcattattagtc	42
55	Kps	KpsM.500-5	TTACTACGCATAAAATTCATGG	43
		KpsR3.500-3	AATTAACCATATCTTTTGATTTGAG	44
		KpsR3.GB-L5	TGCTCGATGAGTTTTTCTAAatcagactgtctttatcag	45

(continued)

	Target gene	Primer name	Sequence	SEQ ID No:
	Primers used to generate deletion mutants			
5		KpsM.GB.L-3	gattttgagacacacacgtggctttcttgccatTTGGTGATGTGATCCT	46
		KpsM.ext-5	TCGCATGCGTTCTGGTTTGAG	47
		KpsR3.ext-3	cctagcaacaaaatatttagcgac	48
	Kp95-	Kps95-96.500-aaacaatatcatggccagtcgg		49
10		Kps95-96.500- aataacgttcaggtattgaagg		50
	Kps95-96.GB-	TGCTCGATGAGTTTTTCTAAccttgaGGTCTATATAACTGAA		51
	Kps95-96.GB-	gattttgagacacacacgtggctttcatcaaatgtaccaagggtgataac		52
	Kps95-96.ext-	taaatcaacgttactgagaatg		53
	Kps95-96.ext-	gaatatccgagtgcataatacc		54
15	Kps95-96-500-	aaacaatatcatggccagtcgg		55
	C3694	c3694.500-5	aagcattagaattggaaccc	56
		c3694.500-3	ctttccatgtattctctccaag	57
	c3694.GB.L-5	TGCTCGATGAGTTTTTCTAAgtgcaagtatttctgtaaccc		58
20	c3694.GB.L-3	GATTTTGAGACACAACGTGGCTTTCATatacgcatcaatagccttagccc		59
	c3694.ext-5	gcggagagctattttaaagcagg		60
	c3694.ext-3	cggaaaacgatatgacaatcctg		61
	C3693	c3693.500-5	gtttattgttcagggcatccaag	62
25		c3693.500-3	atgccgtagatagtttattcc	63
	c3693.GB.L-5	TGCTCGATGAGTTTTTCTAAatggatgctcaaaaggaggtacg		64
	c3693.GB.L-3	GATTTTGAGACACAACGTGGCTTTCATcagcattggttgtaatgcatttg		65
	c3693.ext-5	acatattaacagtaataataacc		66
	c3693.ext-3	ctacaaatttgatactgcaaatc		67
30	C3692	c3692.500-5	ttatacttgcggtgatttcag	68
		c3692.500-3	ATGACTCATAAAAAATATATTCC	69
	c3692.GB.L-5	TGCTCGATGAGTTTTTCTAAtatttacagaataattattctgg		70
	c3692.GB.L-3	GATTTTGAGACACAACGTGGCTTTCATaagccaatagcttgactcatcg		71
35	c3692.ext-5	aattcatatgattgtagcaatg		72
	c3692.ext-3	CAACGTAGAATAAAAGCATTACC		73
	luxS	LuxS.500-5	AAACTGCGCAGTTCCCGTTACC	74
		LuxS.500-3	CCTGATTTTGTTCCCTGGGAGG	75
40	LuxS.GB-L5	TGCTCGATGAGTTTTTCTAATCAGTGGAACAAAAGAAG		76
	LuxS.GB-L3	gattttgagacacacacgtggctttcatTTAGCCACCTCCGGTAATTT		77
	LuxS.ext-5	CTGGAACCGGGTGATCCTCGAAG		78
	LuxS.ext-3	AGCAACAATGCTGGGGAAAAATGC		79
45	Primers used for			
		Kps95-F	aacgaaaattgctgctctggc	80
		Kps94-R	cggtgccaagttgaataacg	81
		Kps94-F	gaaaatagtagacgggtctcttc	82
50		Kps92-R	tttgatactgcaaatcaccgc	83
		KpsIlf	GCGCATTTGCTGATACTGTTG	84
		KpsK2r	AGGTAGTTCAGACTCACACCT	85
	Primers used to check			
55		KmGB.verif-5	TGGCTCCCTCACTTTCTGGC	86

(continued)

Primers used to check			
	KmGB.verif-	3 ATATGGCTCATAACACCCCTTG	87
Primers used for			
	ARB1	ggCCACgCgTCgACTAgTAC,'NNNNNNNNNNgATAT	88
	ARB6	ggCCACgCgTCgACTAgTACNNNNNNNNNNACgCC	89
	ARB2	ggCCACgCgTCgACTAgTAC	90
	IR2	CTgACCgCTTCCTCgTgCTTTACgg	91
	IR2-60-5	TTCTGAgcgggactctgggtacg	92

Analysis of the physico-chemical properties of the active fractions

[0039] Zeta potential was measured as in (Caruso et al., 1999) after 20 minutes of incubation of 10 μ m in diameter cationic colloids latex particles with dialyzed precipitated supernatants (*i.e.*, the level (ii) of purification indicated above). The latex particles bear permanent net positive charge due to their polyethylenimine (PEI) coating. The layer of PEI is a branched 6400 dalton molecular weight polymer bearing approximatively 50% of methylated quaternary functions which confer a stable positive charge to the molecule. This polymer was deposited in aqueous phase on the initially carboxylated particles (Decher, 1997). Hydrophilic properties of the supernatants were investigated by determining the contact angle formed by a 2.5 μ l ultrapure water droplet with a glass plane surface previously incubated in the supernatants for 20 minutes. Surface interactions were analyzed by monitoring the adsorption of propidium iodide on supernatant-treated cationic colloids. The affinity of the treated surfaces for the fluorescent probe was tested using flow cytometry (Leboeuf and Henry, 2006) and fluorescence microscopy. All incubations of particles with supernatant were performed at low particle/volume fraction (ca. 0.2%) likely leading to surface saturation by the active species.

In vivo mice experiments

[0040] CFT073 and CFT073 Δ R1 *in vivo* colonization were performed as described previously (Maroncle et al., 2006). Mice were intragastrically fed with 10¹⁰ CFU. Bacteria contained in fecal samples were numbered on agar plates. For examination of bacterial growth in the host, mice were sacrificed at various times after inoculation; colon and caecum were homogenized in physiological water, and plated to determine cfu per gram of tissue.

Example 2: anti-biofilm activity of CFT073 supernatant

[0041] In order to study UPEC interactions within multicellular biofilm (Hall-Stoodley et al., 2004) bacterial communities, an *in vitro* mixed bacterial biofilm model in microfermentors was developed (Ghigo, 2001). Using this model, a 8 hours biofilm formed by the commensal strain of *E. coli* K12 MG1655 F' was inoculated with different titers of the UPEC strain CFT073, and further cultivated for 24 hours. Upon increasing titers of CFT073, a strong reduction of the *E. coli* K12 MG1655 F' biofilm development was observed, which was not observed when the commensal *E. coli* strain KS272 was used (Fig. 1A). This suggested that CFT073 could prevent MG1655 F' biofilm formation either by direct contact or by secretion of an inhibitory molecule. To distinguish between these two possibilities, the supernatant of CFT073 stationary phase culture was filter-sterilized and its effect on *E. coli* biofilm formation was tested. In the presence of CFT073 supernatant, MG1655 F' biofilm was severely affected (Fig. 1B,C). This biofilm inhibition did not result from a growth defect due to a bactericidal or bacteriostatic activity, since MG1655 F' growth rate and cell viability were not affected by the CFT073 supernatant (Fig. 1D,E).

[0042] In order to determine the spectrum of the anti-biofilm activity of CFT073 supernatant, its effect was tested on several adherent bacteria (*E. coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *S. epidermidis* and *Enterococcus faecalis*). This analysis showed that CFT073 supernatant was active against a surprisingly wide range of bacteria, even in mixed cultures (Fig. 1F and Fig. 2).

Example 3: Correlation between anti-biofilm activity and type-II capsule

[0043] To elucidate the genetic basis of the anti-biofilm effect, the supernatant activity of ca. 10,000 CFT073 random *mariner* transposon insertion mutants was tested. The inventors identified seven candidates impaired in their ability to inhibit MG1655 F' biofilm formation. All these mutants mapped in genes involved in the expression of the group II capsular polysaccharide, the outermost bacterial cell surface structure (Whitfield and Roberts, 1999). Group II capsule displays

a conserved modular genetic organization characterized by 3 functional regions (Roberts, 1996) (Fig. 3A). Region 1 (*kpsFEDCUS*) and region 3 (*kpsMT*) are conserved in all group 11 capsulated bacteria and encode proteins required for the ABC-dependent polysaccharide export. Region 2 is variable and encodes polysaccharide serotypes such as K1, K2 (CFT073), K5, K96 (Roberts, 1996). The R1, R2 or R3 region, or each individual *kps* gene was deleted and it was observed that, except for *kpsU*, *c3692* and *c3693*, all the mutants lost the ability to inhibit *E. coli* biofilm formation, which correlated with a reduced amount of precipitated sugars in the supernatant (Fig. 3B, 3C). While a ferritin-stained capsule could still be detected around CFT073 cells (Fig. 3D), these results indicated that the CFT073 capsule nevertheless undergoes a significant release into the medium supernatant that is responsible for the observed anti-biofilm effect.

[0044] In order to determine whether biofilm inhibition was an exclusive property of *E. coli* CFT073 supernatant, the inventors screened several clinical uropathogenic bacterial isolates of *Klebsiella*, *Proteus*, *Enterobacter*, *Morganella*, *Citrobacter* and *Serratia*, as well as a collection of 110 *E. coli* strains of diverse origins. They found that only the filtered supernatant of 40 *E. coli*, including 17 UPEC, inhibited biofilm formation on a wide range of bacteria without affecting growth rate (Fig. 4A). Moreover, as CFT073 *E. coli* strain, all active strains are able to inhibit biofilm formation of adherent bacteria other than *E. coli* (in Fig. 4A see 15981 *S. aureus* biofilm data). Using specific PCR probes (Johnson and O'Bryan, 2004), they showed that 39 of the 40 active *E. coli* strains carried group II capsule genes. The 40th bacterium, EcoR47, seems in fact to produce a hybrid group II/group III capsule. This strain has been shown to carry group II KPS genes (Boyd and Hartl, 1998). Consistently, the introduction of a *kpsD* mutation into the clinical UPEC isolates U-9 and U-15 abolished the biofilm-inhibitory effect of their supernatants (Fig. 4B). Interestingly, although CFT073, U-9 and U-15 strains displayed a very limited ability to form biofilm in the microfermentor biofilm model, their respective *kpsD* mutants displayed an increased biofilm phenotype. This phenotype could be reverted upon the addition of CFT073 supernatant, suggesting that these strains could also self-inhibit their own adhesion (Fig. 4C).

[0045] A biofilm formation inhibition test was also performed with a strain of *Neisseria meningitidis*, the capsule of which is biochemically very similar to the group II capsule of *E. coli*. Interestingly, the results show that the supernatant of *N. meningitidis* also inhibits the biofilm formation of *E. coli* MG1655F' (Fig. 5), demonstrating that anti-biofilm activity is a property not only of the group II capsule from *E. coli* but also of capsules known to be similar to the latter (*i.e.*, group II-like capsules).

Example 4: Physico-chemical properties of the CFT073 supernatant

[0046] When the inventors analyzed the composition of the polysaccharidic fractions precipitated from the active supernatants of different group II capsule *E. coli* serotypes, including CFT073 (K2), U-9 (non-K2) and IHE3034 (K1), they observed, in agreement with previous studies (Jann et al., 1980; Silver and Vimr, 1984), that these fractions displayed significantly different compositions (data not shown). This suggested that, although biochemically distinct, group II capsules released by these strains could share a similar mode of action leading to biofilm inhibition. To further study the mechanisms by which group II capsule inhibit bacterial biofilm formation, these fractions were brought into contact with cationic colloids composed of 10 μ m in diameter latex particles bearing permanent net positive charge due to their polyethylenimine coating. The determination of the interface ζ (Zeta) potential showed that the wild-type supernatants induced a strong charge inversion of the cationic colloids, indicative of their highly anionic nature as compared to the supernatants of their respective capsule mutants (Fig. 6a). Moreover, the treatment of acid-cleaned glass slides with active supernatant lowered the water-slide interfacial energy, which is indicative of their hydrophilic nature (Fig. 6b).

[0047] To analyze whether group II capsule could induce surface modifications and affect intermolecular forces on the treated surfaces, the inventors monitored the adsorption of propidium iodide, a fluorescent amphiphilic cationic ion, on colloids coated with active or inactive supernatants. They first showed that anionic but inactive supernatant of the non-group II capsulated *E. coli* EcoR72 displayed strong affinity for the cationic fluorescent probe (Fig. 6c). Despite their high negative charge, active supernatants displayed significantly lower probe affinity than inactive but less negatively charged capsule mutant supernatants (Fig. 6c and 6d). This effect was even more pronounced with the 500 kDa K2 capsular active fraction (FR2) purified from CFT073 by anion exchange-chromatography containing galactose, glycerol, phosphate and acetate in the molar ratio of 1: 2: 1: 1 (Jann et al., 1980) (Fig. 6c and 6d). Therefore, these results showed that, besides strong electrostatic modifications, active supernatants also induced a profound remodelling of the colloid surface properties, possibly including surface hydration and steric repulsion. These analyses confirm that the surface modifications induced by group 11 capsule are more critical for the biofilm inhibition activity than the capsule primary composition.

Example 5: Prevention of biofilm development

[0048] The physico-chemical properties displayed by group II capsule might deeply alter bacterial ability to interact with surfaces and therefore drastically reduce adhesion (Neu, 1996). To test this hypothesis, the capacity of both MG1655 F' and *S. aureus* to adhere to glass surfaces pre-treated with CFT073 supernatant was analysed. After 1 hour of incubation,

E. coli MG1655 F' and *S. aureus* 15981 exhibited a 3-fold reduction in their initial adhesion on treated surface (data not shown). Consistently, pretreatment of the internal microfermentor glass slide with CFT073 supernatant drastically reduced biofilm formation by *E. coli* and a wide range of Gram-positive and Gram-negative bacteria (Fig. 7). The same effect was observed when CFT073 supernatant was perfused in the microfermentor (Fig. 2B). No effect was observed when a similar treatment was performed with CFT073 Δ kpsD supernatant (Fig. 7). These results therefore suggested that the surface modifications induced by capsular polysaccharides released in the CFT073 supernatant could interfere with biofilm formation by impairing initial bacterial-surface interactions.

[0049] Remarkably, the anti-biofilm effect of the CFT073 supernatant persisted even after drastic treatments of the glass slide (Fig. 8), which suggests that the group II capsule could be used in applications which necessitate a sterilisation step (such as agro-industrial or medical applications).

[0050] In order to investigate the effect of CFT073 supernatant on already existing biofilms, microfermentors inoculated with MG1655 F' at different stages of biofilm maturation were supplemented with filtered CFT073 supernatant. This analysis showed that, whereas the treatment of a mature 24 h biofilm did not induce biofilm dispersal, addition of the CFT073 supernatant at 0, 1 and 6 h after MG1655 F' biofilm initiation blocked its further development (Fig. 9A). The inventors then examined the *in vitro* biofilm characteristics of a GFP-tagged MG1655F' after addition of CFT073 supernatant and confocal laser scanning microscopy (CLSM). After 3h post initial inoculation, the addition of active CFT073 exogenous supernatant on a regularly covered surface profoundly affected MG1655F' mature biofilm structure development (Fig 9B). This effect was not observed upon control KS272 supernatant treatment.

[0051] The direct contribution of bacterial surface structures to the tridimensional *E. coli* biofilm structure has been amply demonstrated (Beloin et al., 2005). These structures have also been shown to mediate bacterial aggregation and clumping in standing cultures. To further characterize the role of group II capsule in biofilm maturation, the inventors tested its effects on bacterial aggregation mediated by several different surface-exposed factors also involved in biofilm formation. It was shown that CFT073 supernatant prevents formation of bacterial aggregates induced by different types of bacterial surface structures (Fig. 9C).

[0052] The anti-biofilm activity of different concentrations of the FR2 fraction was tested in microtiter plate assays. This showed that the purified FR2 fraction is active at concentrations starting from 50 μ g/ml (Fig. 10).

[0053] Taken together, these results suggest that the physico-chemical properties of the group II capsular polysaccharides affect biofilm formation by weakening cell-surface contacts (initial adhesion) but also by reducing cell-cell interactions (biofilm maturation).

[0054] In conclusion, the inventors demonstrated that group II-like capsular polysaccharides are released in the culture supernatant and display anti-adhesion properties against a wide range of bacteria, including important nosocomial pathogens. This study reveals a novel property of the group II capsular polysaccharides that are commonly expressed by extra-intestinal *E. coli*, but also by other pathogens such as *Neisseria meningitides* (Kajiser, 1973; Sandberg et al., 1988), which supernatant could also inhibit *E. coli* biofilm formation (data not shown). Group II capsule has been shown to be involved in UPEC virulence by increasing their resistance to phagocytosis and to the bactericidal effects of human serum (Cross et al., 1986; Kaper et al., 2004; Pluschke et al., 1983; Russo et al., 1995). Capsule could also play an important biological role in UPEC interactions with living and inert surfaces. In particular, besides bacterial competition, the inhibition of UPEC own adhesion by group II capsule secretion may contribute to gastrointestinal tract colonisation by reducing bacteria-bacteria interactions (Schembri et al., 2004), thus avoiding bacterial clearance due to clump formation (Favre-Bonte et al., 1999). Consistently, it was observed that an uncapsulated CFT073 Δ RI mutant is unable to colonize the mouse intestine (Fig. 11).

[0055] The *in vitro* analyses indicate that group II capsule can induce surface modifications such as charge inversion of cationic surface, increased surface wettability and molecular repulsion, leading to non-specific anti-adhesion properties. Since this inhibitory effect was observed in both exponential and stationary growth phase supernatants as well as in a quorum-sensing Δ luxS mutant of CFT073 (Fig. 12), this suggests that the anti-biofilm effect does not involve cell-signaling (Waters and Bassler, 2005), but rather acts through physico-chemical alteration, of either abiotic or bacterial surfaces. Polymers assembling on surfaces are known to cause strong physical repulsion depending on their density, size, solvation and structure (de Gennes, 1987). Such repulsive forces created by capsule polymers could limit initial bacterial adhesion and biofilm development by interfering with subsequent cell-cell contacts. Finally, the inventors showed that the application of group II capsular polysaccharides on abiotic surfaces reduces bacterial initial adhesion, and has enough long-lasting effect to significantly inhibit mature biofilm development of a broad-spectrum of bacteria. This finding may have far reaching implications in the design of therapeutic strategies to limit the formation of pathogenic biofilms, for example, on medical implants.

REFERENCES

[0056]

- Bahrani-Mougeot, F. K., Buckles, E. L., Lockett, C. V., Hebel, J. R., Johnson, D. E., Tang, C. M., and Donnenberg, M. S. (2002). Type 1 fimbriae and extracellular polysaccharides are preeminent uropathogenic *Escherichia coli* virulence determinants in the murine urinary tract. *Mol Microbiol* 45, 1079-1093.
- Beloin, C., Da Re, S. & Ghigo, J. M. (2005) in *Escherichia coli and Salmonella Cellular and Molecular Biology*, eds. Curtiss III, R., Böck, A., Ingraham, J. L., Kaper, J. B., Neidhardt, F. C., Riley, M. & Squires, C. L. (ASM Press, Washington, D.C.), pp. Chapter 8.3.1.3.
- Beloin, C., Michaelis, K., Lindner, K., Landini, P., Hacker, J., Ghigo, J. M., and Dobrindt, U. (2006). The Transcriptional Antiterminator RfaH Represses Biofilm Formation in *Escherichia coli*. *J Bacteriol* 188, 1316-1331.
- Boyd, E. F., and Hartl, D. L. (1998). Chromosomal regions specific to pathogenic isolates of *Escherichia coli* have a phylogenetically clustered distribution. *J Bacteriol* 180, 1159-1165.
- Caruso, F., Lichtenfeld, H., Donath, E., and Möhwald, H. (1999). Investigation of electrostatic interactions in poly-electrolyte multilayer films: binding of anionic fluorescent probes to layers assembled onto colloids. *Macromolecules* 32, 2317-2328.
- Christensen, B. B., Sternberg, C., Andersen, J. B., Palmer, R. J., Jr., Nielsen, A. T., Givskov, M., and Molin, S. (1999). Molecular tools for study of biofilm physiology. *Methods Enzymol* 310, 20-42.
- Cross, A. S., Kim, K. S., Wright, D. C., Sadoff, J. C., and Gemski, P. (1986). Role of lipopolysaccharide and capsule in the serum resistance of bacteremic strains of *Escherichia coli*. *J Infect Dis* 154, 497-503.
- Cucarella, C., Solano, C., Valle, J., Amorena, B., Lasa, I. I., and Penades, J. R. (2001). Bap, a *Staphylococcus aureus* Surface Protein Involved in Biofilm Formation. *J Bacteriol* 183, 2888-2896.
- Da Re, S., and Ghigo, J. M. (2006). A CsgD-independent pathway for cellulose production and biofilm formation in *Escherichia coli*. *J Bacteriol* 188, in press.
- de Gennes, P. G. (1987). Polymers at an interface: a simplified view. *Adv Colloid Interface Sci* 27, 189-209.
- Decher, G. (1997). Fuzzy Nanoassemblies: Toward Layered Polymeric Multicomposites. *Science* 277, 1232-1237.
- Deghmane, A. E., Giorgini, D., Larribe, M., Alonso, J. M., and Taha, M. K. (2002). Down-regulation of pili and capsule of *Neisseria meningitidis* upon contact with epithelial cells is mediated by CrgA regulatory protein. *Mol Microbiol* 43, 1555-1564.
- d'Enfert, C., and Fontaine, T. (1997). Molecular characterization of the *Aspergillus nidulans* treA gene encoding an acid trehalase required for growth on trehalose. *Mol Microbiol* 24, 203-216.
- Dubois, M., Gilles, K. A., Hamilton, J. K., Rebers, P. A., and Smith, F. (1956). Colorimetric method for determination of sugars and related substances. *Anal Chem* 28, 350-356.
- Favre-Bonte, S., Licht, T. R., Forestier, C., and Krogfelt, K. A. (1999). *Klebsiella pneumoniae* capsule expression is necessary for colonization of large intestines of streptomycin-treated mice. *Infect Immun* 67, 6152-6156.
- Fontaine, T., Simenel, C., Dubreucq, G., Adam, O., Delepierre, M., Lemoine, J., Vorgias, C. E., Diaquin, M., and Latge, J. P. (2000). Molecular organization of the alkali-insoluble fraction of *aspergillus fumigatus* cell wall. *J Biol Chem* 275, 41528.
- Galdbart, J. O., Allignet, J., Tung, H. S., Ryden, C., and El Solh, N. (2000). Screening for *Staphylococcus epidermidis* markers discriminating between skinflora strains and those responsible for infections of joint prostheses. *J Infect Dis* 182, 351-355.
- Ghigo, J. M. (2001). Natural conjugative plasmids induce bacterial biofilm development. *Nature* 412, 442-445.
- Hall-Stoodley, L., Costerton, J. W., and Stoodley, P. (2004). Bacterial biofilms: from the natural environment to infectious diseases. *Nat Rev Microbiol* 2, 95-108.
- Heilmann, C., Gerke, C., Perdreau-Remington, F., and Gotz, F. (1996). Characterization of Tn917 insertion mutants of *Staphylococcus epidermidis* affected in biofilm formation. *Infect Immun* 64, 277-282.
- Jann, K., Jann, B., Schmidt, M. A., and Vann, W. F. (1980). Structure of the *Escherichia coli* K2 capsular antigen, a teichoic acid-like polymer. *J Bacteriol* 143, 1108-1115.
- Johnson, J. R., and O'Bryan, T. T. (2004). Detection of the *Escherichia coli* group 2 polysaccharide capsule synthesis Gene kpsM by a rapid and specific PCR-based assay. *J Clin Microbiol* 42, 1773-1776.
- Kaijser, B. (1973). Immunology of *Escherichia coli*: K antigen and its relation to urinary-tract infection. *J Infect Dis* 127, 670-677.
- Kaper, J. B., Nataro, J. P., and Mobley, H. L. (2004). Pathogenic *Escherichia coli*. *Nat Rev Microbiol* 2, 123-140.
- Leboeuf, D., and Henry, N. (2006). Molecular bond formation between surfaces: anchoring and shearing effects. *Langmuir* 22, 127-133.
- Maroncle, N., Rich, C., and Forestier, C. (2006). The role of *Klebsiella pneumoniae* urease in intestinal colonization and resistance to gastrointestinal stress. *Res Microbiol* 157, 184-193.
- Meier, C., Oelschlaeger, T. A., Merkert, H., Korhonen, T. K., and Hacker, J. (1996). Ability of *Escherichia coli* isolates that cause meningitis in newborns to invade epithelial and endothelial cells. *Infect Immun* 64, 2391-2399.
- Mobley, H. L., Green, D. M., Trifillis, A. L., Johnson, D. E., Chippendale, G. R., Lockett, C. V., Jones, B. D., and Warren, J. W. (1990). Pyelonephritogenic *Escherichia coli* and killing of cultured human renal proximal tubular

epithelial cells: role of hemolysin in some strains. *Infect Immun* 58, 1281-1289.

Neu, T. R. (1996). Significance of bacterial surface-active compounds in interaction of bacteria with interfaces. *Microbiol Rev* 60, 151-166.

Ochman, H., and Selander, R. K. (1984). Standard reference strains of *Escherichia coli* from natural populations. *J Bacteriol* 157, 690-693.

O'Toole, G. A., and Kolter, R. (1998). Initiation of biofilm formation in *Pseudomonas fluorescens* WCS365 proceeds via multiple, convergent signalling pathways: a genetic analysis. *Mol Microbiol* 28, 449-461.

Pluschke, G., Mayden, J., Achtman, M., and Levine, R. P. (1983). Role of the capsule and the O antigen in resistance of O18:K *Escherichia coli* to complement-mediated killing. *Infect Immun* 42, 907-913.

Roberts, I. S. (1996). The biochemistry and genetics of capsular polysaccharide production in bacteria. *Annu Rev Microbiol* 50, 285-315.

Russo, T. A., Sharma, G., Weiss, J., and Brown, C. (1995). The construction and characterization of colanic acid deficient mutants in an extraintestinal isolate of *Escherichia coli* (O4/K54/H5). *Microb Pathog* 18, 269-278.

Sandberg, T., Kaijser, B., Lidin-Janson, G., Lincoln, K., Orskov, F., Orskov, I., Stokland, E., and Svanborg-Eden, C. (1988). Virulence of *Escherichia coli* in relation to host factors in women with symptomatic urinary tract infection. *J Clin Microbiol* 26, 1471-1476.

Schachter, B. (2003). Slimy business--the biotechnology of biofilms. *Nat Biotechnol* 21, 361-365.

Schembri, M. A., Dalsgaard, D., and Klemm, P. (2004). Capsule shields the function of short bacterial adhesins. *J Bacteriol* 186, 1249-1257.

Silver, R. P., and Vimr, E. R. (1984). Polysialic acid capsule of *Escherichia coli* K1. In *Molecular Basis of Bacterial Pathogenesis* (Academic Press, Inc., New York), pp. 39-60.

Strauch, K. L., and Beckwith, J. (1988). An *Escherichia coli* mutation preventing degradation of abnormal periplasmic proteins. *Proc Natl Acad Sci U S A* 85, 1576-1580.

Toledo-Arana, A., Valle, J., Solano, C., Arrizubieta, M. J., Cucarella, C., Lamata, M., Amorena, B., Leiva, J., Penades, J. R., and Lasa, I. (2001). The Enterococcal Surface Protein, Esp, Is Involved in *Enterococcus faecalis* Biofilm Formation. *Appl Environ Microbiol* 67, 4538-4545.

Valle, J., Toledo-Arana, A., Berasain, C., Ghigo, J. M., Amorena, B., Penades, J. R., and Lasa, I. (2003). SarA and not sigmaB is essential for biofilm development by *Staphylococcus aureus*. *Mol Microbiol* 48, 1075-1087.

Vasseur, P., Vallet-Gely, I., Soscia, C., Genin, S., and Filloux, A. (2005). The *pel* genes of the *Pseudomonas aeruginosa* PAK strain are involved at early and late stages of biofilm formation. *Microbiology* 151, 985-997.

Vidal, O., Longin, R., Prigent-Combaret, C., Dorel, C., Hooreman, M., and Lejeune, P. (1998). Isolation of an *Escherichia coli* K-12 mutant strain able to form biofilms on inert surfaces: involvement of a new *ompR* allele that increases curli expression. *J Bacteriol* 180, 2442-2449.

Waters, C. M., and Bassler, B. L. (2005). Quorum sensing: cell-to-cell communication in bacteria. *Annu Rev Cell Dev Biol* 21, 319-346.

Whitfield, C. (2006). Biosynthesis and assembly of capsular polysaccharides in *Escherichia coli*. *Annu Rev Biochem* 75, 39-68.

Whitfield, C., and Roberts, I. S. (1999). Structure, assembly and regulation of expression of capsules in *Escherichia coli*. *Mol Microbiol* 31, 1307-1319.

SEQUENCE LISTING

[0057]

<110> INSTITUT PASTEUR
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
GHIGO, Jean-Marc
VALLE, Jaione
DA RE, Sandra

<120> USE OF BACTERIAL POLYSACCHARIDES FOR BIOFILM INHIBITION.

<130> VMA/ahF226/127

<160> 92

<170> PatentIn version 3.3

<210> 1
 <211> 24
 <212> DNA
 <213> Artificial
 5
 <220>
 <223> KpsD.500-5
 <400> 1
 10 gaccagcttg cctttgcaga aacg 24
 <210> 2
 <211> 24
 <212> DNA
 15 <213> Artificial
 <220>
 <223> KpsD.500-3
 20 <400> 2
 cttttcagc attacgcgga tagg 24
 <210> 3
 <211> 37
 25 <212> DNA
 <213> Artificial
 <220>
 <223> KpsD.GB.L-5
 30 <400> 3
 tgctcgatga gttttctaa ggagtgaaa tgagcaa 37
 <210> 4
 35 <211> 47
 <212> DNA
 <213> Artificial
 <220>
 40 <223> KpsD.GB.L-3
 <400> 4
 gattttgaga cacaacgtgg ctttcatcac aaactcattc agcgaca 47
 45 <210> 5
 <211> 24
 <212> DNA
 <213> Artificial
 50 <220>
 <223> KpsD.ext-5
 <400> 5
 55 ttgcgcttaa gtttaaccaa accg 24
 <210> 6
 <211> 24
 <212> DNA

<213> Artificial
 <220>
 <223> KpsD.ext-3
 5
 <400> 6
 gctctggcat ggactccggt aact 24
 <210> 7
 10 <211> 25
 <212> DNA
 <213> Artificial
 <220>
 15 <223> KpsU.500-5
 <400> 7
 atgaacgcag ttcagcttta tcgcc 25
 20 <210> 8
 <211> 24
 <212> DNA
 <213> Artificial
 25 <220>
 <223> KpsU.500-3
 <400> 8
 30 ccaaatttcg gcttgaggat tttc 24
 <210> 9
 <211> 44
 <212> DNA
 <213> Artificial
 35 <220>
 <223> KpsU.GB.L-5
 <400> 9
 40 tgctcgatga gttttctaa caggaactgg ctgaaaacgc atga 44
 <210> 10
 <211> 49
 <212> DNA
 45 <213> Artificial
 <220>
 <223> KpsU.GB.L-3
 50 <400> 10
 gattttgaga cacaacgtgg ctttcatttc aactccttac aaagacaga 49
 <210> 11
 <211> 24
 55 <212> DNA
 <213> Artificial
 <220>

<223> KpsU.ext-5

 <400> 11
 tgcagaacgg cgatacctta atcg 24
 5

 <210> 12
 <211> 24
 <212> DNA
 <213> Artificial
 10

 <220>
 <223> KpsU.ext-3

 <400> 12
 ctcggcaatc aaacgtactc gttg 24
 15

 <210> 13
 <211> 22
 <212> DNA
 <213> Artificial
 20

 <220>
 <223> KpsC.500-5

 <400> 13
 gaggcagata tcaacattaa cc 22
 25

 <210> 14
 <211> 23
 <212> DNA
 <213> Artificial
 30

 <220>
 <223> KpsC.500-3
 35

 <400> 14
 gttgaagggt ttaagttctc aac 23

 <210> 15
 <211> 43
 <212> DNA
 <213> Artificial
 40

 <220>
 <223> KpsC.GB.L-5
 45

 <400> 15
 tgctcgatga gttttctaa acaatttcac agttgactat tac 43
 50

 <210> 16
 <211> 49
 <212> DNA
 <213> Artificial
 55

 <220>
 <223> KpsC.GB.L-3

 <400> 16

gattttgaga cacaacgtgg ctttgagtaa atgccaatca tgcgttttc 49

<210> 17

<211> 22

5 <212> DNA

<213> Artificial

<220>

10 <223> KpsC.ext-5

<400> 17

cgactcacat tacgattatg cg 22

<210> 18

15 <211> 25

<212> DNA

<213> Artificial

<220>

20 <223> KpsC.ext-3

<400> 18

gaaaatgatt tgtggtggcg gtagc 25

<210> 19

25 <211> 22

<212> DNA

<213> Artificial

<220>

30 <223> KpsS.500-5

<400> 19

agagcaacct tgagttatta cg 22

<210> 20

35 <211> 22

<212> DNA

<213> Artificial

<220>

40 <223> KpsS.500-3

<400> 20

45 aaagacaagg gatagcttta gg 22

<210> 21

<211> 40

<212> DNA

50 <213> Artificial

<220>

<223> KpsS.GB.L-5

<400> 21

55 tgctcgatga gttttctaa ttattctaa attatcaacg 40

<210> 22

<211> 49
 <212> DNA
 <213> Artificial
 5 <220>
 <223> KpsS.GB.L-3
 <400> 22
 gattttgaga cacaacgtgg ctttcataaa taatctgtgt aatagtcaa 49
 10
 <210> 23
 <211> 23
 <212> DNA
 <213> Artificial
 15
 <220>
 <223> KpsS.ext-5
 <400> 23
 20 agcgactggt tgaagcaaa ctg 23
 <210> 24
 <211> 22
 <212> DNA
 25 <213> Artificial
 <220>
 <223> KpsS.ext-3
 30 <400> 24
 ttcgatgagt caagactatt gg 22
 <210> 25
 <211> 22
 35 <212> DNA
 <213> Artificial
 <220>
 <223> KpsM.500-5
 40
 <400> 25
 ttactacgca taaaattcat gg 22
 <210> 26
 45 <211> 23
 <212> DNA
 <213> Artificial
 <220>
 50 <223> KpsM.500-3
 <400> 26
 aatgccatgc ttaaaccaaa gcc 23
 55
 <210> 27
 <211> 46
 <212> DNA
 <213> Artificial

<220>
 <223> KpsM.GB.L-5

 <400> 27
 5 tgctcgatga gttttctaa caatgctgac atcatgatta agattg 46

 <210> 28
 <211> 48
 <212> DNA
 10 <213> Artificial

 <220>
 <223> KpsM.GB.L-3

 15 <400> 28
 gatattgaga cacaacgtgg ctttcttgcc atttggtgat gtgacct 48

 <210> 29
 <211> 21
 20 <212> DNA
 <213> Artificial

 <220>
 <223> KpsM.ext-5
 25
 <400> 29
 tcgcatgcgt tctggttga g 21

 <210> 30
 30 <211> 23
 <212> DNA
 <213> Artificial

 <220>
 35 <223> KpsM.ext-3

 <400> 30
 cacatcacia aactcttca atg 23

 40 <210> 31
 <211> 24
 <212> DNA
 <213> Artificial

 45 <220>
 <223> KpsD.500-5

 <400> 31
 50 gaccagcttg cctttgcaga aacg 24

 <210> 32
 <211> 22
 <212> DNA
 <213> Artificial
 55
 <220>
 <223> KpsS.500-3

<400> 32
 aaagacaagg gatagcttta gg 22

 <210> 33
 <211> 47
 <212> DNA
 <213> Artificial

 <220>
 <223> KpsD.GB.L-3

 <400> 33
 gattttgaga cacaacgtgg ctttcatcac aaactcattc agcgaca 47

 <210> 34
 <211> 49
 <212> DNA
 <213> Artificial

 <220>
 <223> KpsS.GB.L-3

 <400> 34
 gattttgaga cacaacgtgg ctttcataaa taatctgtgt aatagtcaa 49

 <210> 35
 <211> 24
 <212> DNA
 <213> Artificial

 <220>
 <223> KpsD.ext-5

 <400> 35
 ttgcgcttaa gtttaaccaa accg 24

 <210> 36
 <211> 22
 <212> DNA
 <213> Artificial

 <220>
 <223> KpsS.ext-3

 <400> 36
 ttcgatgagt caagactatt gg 22

 <210> 37
 <211> 22
 <212> DNA
 <213> Artificial

 <220>
 <223> KpsR2.500-5

 <400> 37
 atataggagt atggagcgaa ac 22

<210> 38
 <211> 22
 <212> DNA
 <213> Artificial
 5
 <220>
 <223> KpsR2.500-3
 <400> 38
 10 ttgagtaagg aatatggctt ag 22
 <210> 39
 <211> 38
 <212> DNA
 15 <213> Artificial
 <220>
 <223> KpsR2.GB-L5
 20 <400> 39
 tgctcgatga gttttctaa gaaatcagac gagtttct 38
 <210> 40
 <211> 52
 25 <212> DNA
 <213> Artificial
 <220>
 <223> KpsR2.GB-L3
 30 <400> 40
 gattttgaga cacaacgtgg ctttcataac atactatgtc cccatgatta tt 52
 <210> 41
 35 <211> 23
 <212> DNA
 <213> Artificial
 <220>
 40 <223> KpsR2.ext-5
 <400> 41
 catgtactca ttttcacgta aag 23
 45 <210> 42
 <211> 23
 <212> DNA
 <213> Artificial
 50 <220>
 <223> KpsR2. ext-3
 <400> 42
 55 tgctaaaatt gcattattag gtc 23
 <210> 43
 <211> 22
 <212> DNA

<213> Artificial
 <220>
 <223> KpsM.500-5
 5
 <400> 43
 ttactacgca taaaattcat gg 22
 <210> 44
 10 <211> 25
 <212> DNA
 <213> Artificial
 <220>
 15 <223> KpsR3.500-3
 <400> 44
 aattaaccat atcttttgat ttgag 25
 20 <210> 45
 <211> 40
 <212> DNA
 <213> Artificial
 25 <220>
 <223> KpsR3.GB-L5
 <400> 45
 30 tgctcgatga gttttctaa atcagacttg tctttatcag 40
 <210> 46
 <211> 48
 <212> DNA
 <213> Artificial
 35 <220>
 <223> KpsM.GB.L-3
 <400> 46
 40 gattttgaga cacaacgtgg ctttctgcc atttggtgat gtgacct 48
 <210> 47
 <211> 21
 <212> DNA
 45 <213> Artificial
 <220>
 <223> KpsM.ext-5
 50 <400> 47
 tcgcatgcgt tctggttga g 21
 <210> 48
 <211> 24
 55 <212> DNA
 <213> Artificial
 <220>

<223> KpsR3.ext-3

 <400> 48
 cctagcaaca aaatatttag cgac 24
 5

 <210> 49
 <211> 22
 <212> DNA
 <213> Artificial
 10

 <220>
 <223> Kps95-96.500-5

 <400> 49
 aaacaatatc atggccagtc gg 22
 15

 <210> 50
 <211> 22
 <212> DNA
 <213> Artificial
 20

 <220>
 <223> Kps95-96.500-3

 <400> 50
 aataacgttc aggtattgaa gg 22
 25

 <210> 51
 <211> 42
 <212> DNA
 <213> Artificial
 30

 <220>
 <223> Kps95-96.GB-L5
 35

 <400> 51
 tgctcgatga gttttctaa ccttgaggtc tatataactg aa 42

 <210> 52
 <211> 49
 <212> DNA
 <213> Artificial
 40

 <220>
 <223> Kps95-96.GB-L3
 45

 <400> 52
 gattttgaga cacaacgtgg cttcatcaa atgtaccaa ggtgataac 49
 50

 <210> 53
 <211> 22
 <212> DNA
 <213> Artificial
 55

 <220>
 <223> Kps95-96.ext-5

 <400> 53

	taaatcaacg ttactgagaa tg	22	
	<210> 54		
	<211> 22		
5	<212> DNA		
	<213> Artificial		
	<220>		
10	<223> Kps95-96.ext-3		
	<400> 54		
	gaatatccga gtgcataata cc	22	
	<210> 55		
15	<211> 22		
	<212> DNA		
	<213> Artificial		
	<220>		
20	<223> Kps95-96.500-5		
	<400> 55		
	aaacaatatc atggccagtc gg	22	
25	<210> 56		
	<211> 20		
	<212> DNA		
	<213> Artificial		
30	<220>		
	<223> c3694.500-5		
	<400> 56		
35	aagcattaga attggaaccc	20	
	<210> 57		
	<211> 23		
	<212> DNA		
40	<213> Artificial		
	<220>		
	<223> c3694.500-3		
	<400> 57		
45	ctttccatgt attcctctcc aag	23	
	<210> 58		
	<211> 42		
	<212> DNA		
50	<213> Artificial		
	<220>		
	<223> c3694.GB.L-5		
55	<400> 58		
	tgctcgatga gtttttctaa gtgcaagtat ttcttgaac cc	42	
	<210> 59		

<211> 50
 <212> DNA
 <213> Artificial
 5 <220>
 <223> c3694.GB.L-3
 <400> 59
 gattttgaga cacaacgtgg ctttcatata cgcatcaata gccttagccc 50
 10 <210> 60
 <211> 23
 <212> DNA
 <213> Artificial
 15 <220>
 <223> c3694.ext-5
 <400> 60
 20 gcggagagct attttaaagc agg 23
 <210> 61
 <211> 23
 <212> DNA
 25 <213> Artificial
 <220>
 <223> c3694.ext-3
 30 <400> 61
 cggaacacga tatgacaatc ctg 23
 <210> 62
 <211> 23
 35 <212> DNA
 <213> Artificial
 <220>
 <223> c3693.500-5
 40 <400> 62
 gtttattgtt gcaggcatcc aag 23
 <210> 63
 45 <211> 23
 <212> DNA
 <213> Artificial
 <220>
 50 <223> c3693.500-3
 <400> 63
 atgccgttag atagttttat tcc 23
 55 <210> 64
 <211> 43
 <212> DNA
 <213> Artificial

<220>

<223> c3693.GB.L-5

<400> 64

5 tgctcgatga gttttctaa atggatgctc aaaaggaggt acg 43

<210> 65

<211> 51

<212> DNA

10 <213> Artificial

<220>

<223> c3693.GB.L-3

<400> 65

15 gattttgaga cacaacgtgg ctttcacag cattgggtgg taatgcattt g 51

<210> 66

<211> 22

<212> DNA

20 <213> Artificial

<220>

<223> c3693.ext-5

<400> 66

25 acatattaac agtaataaa cc 22

<210> 67

<211> 24

<212> DNA

30 <213> Artificial

<220>

<223> c3693.ext-3

<400> 67

35 ctacaaattt ggatactgca aatc 24

<210> 68

<211> 22

<212> DNA

40 <213> Artificial

<220>

<223> c3692.500-5

<400> 68

45 ttatactgac ggtgatttgc ag 22

<210> 69

<211> 22

<212> DNA

50 <213> Artificial

<220>

<223> c3692.500-3

<400> 69
 atgactcata aaaatatatt cc 22

 <210> 70
 <211> 43
 <212> DNA
 <213> Artificial

 <220>
 <223> c3692.GB.L-5

 <400> 70
 tgctcgatga gttttctaa tatttacaga ataattattc tgg 43

 <210> 71
 <211> 51
 <212> DNA
 <213> Artificial

 <220>
 <223> c3692.GB.L-3

 <400> 71
 gattttgaga cacaacgtgg ctttcattaa gccaatagtc ttgactcatc g 51

 <210> 72
 <211> 22
 <212> DNA
 <213> Artificial

 <220>
 <223> c3692.ext-5

 <400> 72
 aattcatatg attgtagcaa tg 22

 <210> 73
 <211> 23
 <212> DNA
 <213> Artificial

 <220>
 <223> c3692.ext-3

 <400> 73
 caacgtagaa taaaagcatt acc 23

 <210> 74
 <211> 22
 <212> DNA
 <213> Artificial

 <220>
 <223> LuxS.500-5

 <400> 74
 aaactgcgca gttcccgta cc 22

<210> 75
 <211> 22
 <212> DNA
 <213> Artificial
 5
 <220>
 <223> LuxS.500-3
 <400> 75
 10 cctgatttg ttcctggga gg 22
 <210> 76
 <211> 38
 <212> DNA
 15 <213> Artificial
 <220>
 <223> LuxS.GB-L5
 20 <400> 76
 tgctcgatga gttttctaa tcagtgaac aaaagaag 38
 <210> 77
 <211> 47
 25 <212> DNA
 <213> Artificial
 <220>
 <223> LuxS.GB-L3
 30 <400> 77
 gatttgaga cacaacgtgg ctttcattta gccacctccg gtaattt 47
 <210> 78
 35 <211> 23
 <212> DNA
 <213> Artificial
 <220>
 40 <223> LuxS.ext-5
 <400> 78
 ctggaaccgg gtgatcctcg aag 23
 45 <210> 79
 <211> 24
 <212> DNA
 <213> Artificial
 50 <220>
 <223> LuxS.ext-3
 <400> 79
 55 agcaacaatg ctggggaaaa atgc 24
 <210> 80
 <211> 22
 <212> DNA

<213> Artificial
 <220>
 <223> Kps95-F
 5
 <400> 80
 aacgaaaatt gctgctctg gc 22
 <210> 81
 10 <211> 22
 <212> DNA
 <213> Artificial
 <220>
 15 <223> Kps94-R
 <400> 81
 cggtgccaag ttgaaataa cg 22
 20 <210> 82
 <211> 24
 <212> DNA
 <213> Artificial
 25 <220>
 <223> Kps94-F
 <400> 82
 30 gaaaatagtg tagacggtct cttc 24
 <210> 83
 <211> 22
 <212> DNA
 <213> Artificial
 35 <220>
 <223> Kps92-R
 <400> 83
 40 ttggtact gcaaatcacc gc 22
 <210> 84
 <211> 21
 <212> DNA
 45 <213> Artificial
 <220>
 <223> KpsIIIf
 50 <400> 84
 gcgcatttgc tgatactgtt g 21
 <210> 85
 <211> 21
 55 <212> DNA
 <213> Artificial
 <220>

<223> KpsK2r
 <400> 85
 aggtagtcca gactcacacc t 21
 5
 <210> 86
 <211> 20
 <212> DNA
 <213> Artificial
 10
 <220>
 <223> KmGB.verif-5
 <400> 86
 15 tggctccctc actttctggc 20
 <210> 87
 <211> 22
 <212> DNA
 20 <213> Artificial
 <220>
 <223> KmGB.verif-3
 25 <400> 87
 atatggctca taacaccctt tg 22
 <210> 88
 <211> 35
 30 <212> DNA
 <213> Artificial
 <220>
 <223> ARB1
 35 <220>
 <221> misc_feature
 <222> (21)..(30)
 <223> n is a, c, g, or t
 40 <400> 88
 ggccacgcgt cgactagtac nnnnnnnnnn gatat 35
 <210> 89
 45 <211> 35
 <212> DNA
 <213> Artificial
 <220>
 50 <223> ARB6
 <220>
 <221> misc_feature
 <222> (21)..(30)
 55 <223> n is a, c, g, or t
 <400> 89
 ggccacgcgt cgactagtac nnnnnnnnnn acgcc 35

<210> 90
 <211> 20
 <212> DNA
 <213> Artificial

5

<220>
 <223> ARB2

10

<400> 90
 ggccacgcgt cgactagtag 20

15

<210> 91
 <211> 25
 <212> DNA
 <213> Artificial

20

<220>
 <223> IR2
 <400> 91
 ctgaccgctt cctcgtgctt tacgg 25

25

<210> 92
 <211> 24
 <212> DNA
 <213> Artificial

30

<220>
 <223> IR2-60-5
 <400> 92
 ttctgagcgg gactctgggg tacg 24

35

Claims

40

1. Use of a soluble group II-like capsular polysaccharide from a bacterial strain, for the preparation of a composition which prevents or inhibits bacterial adhesion and/or bacterial biofilm development.

45

2. The use of claim 1, wherein said soluble group II-like capsular polysaccharide is obtained in the supernatant of a culture of bacteria selected amongst *Escherichia coli*, *Hemophilus influenzae* and *Neisseria meningitidis*.

3. The use of claim 1 or claim 2, wherein said soluble group II-like capsular polysaccharide is obtained as a purified fraction.

4. A composition for inhibiting bacterial adhesion and/or bacterial biofilm development, **characterized in that** it comprises a soluble group II-like capsular polysaccharide from a bacterial strain

50

5. The composition of claim 4, which comprises a purified fraction of the supernatant of a culture of bacteria selected amongst *E. coli*, *H. influenzae* and *N. meningitidis*.

6. A process for purifying an anti-biofilm group II-like capsular polysaccharide from a bacterial strain, comprising the following steps:

55

- (i) separating the supernatant of a culture of a bacterial strain expressing a group II-like capsule from the bacterial cells,
- (ii) precipitating the polysaccharides present in the obtained supernatant, and
- (iii) optionally resuspending the precipitate.

7. The process of claim 6, wherein said bacterial strain expressing a group II-like capsule is selected amongst *E. coli*, *H. influenzae* and *N. meningitidis*.
8. The process of claim 6 or claim 7, wherein said bacterial strain is an uropathogenic *E. coli*.
9. The process of any of claims 6 to 8, wherein the separation in step (i) is performed by filter-sterilization and/or by centrifugation of the culture
10. The process of any of claims 6 to 9, wherein the precipitation in step (ii) is performed with three volumes of ethanol for one volume of supernatant.
11. The process of any of claims 6 to 10, wherein the precipitate obtained in step (ii) is resuspended in water, dialyzed against deionised water, and then lyophilized before step (iii).
12. The process of any of claims 6 to 11, further comprising an additional step (iv) of purification by ion exchange chromatography.
13. The process of claim 12, wherein step (iv) is performed using a DEAE-Sepharose column.
14. The process of claim 12 or claim 13, wherein the resuspension in step (iii) is done in TrisHCl 20 mM, pH 7.5, with 25% propanol-1, and the column used in step (iv) is equilibrated with the same buffer.
15. The process of any of claims 12 to 14, wherein a centrifugation step is performed between step (iii) and step (iv) to discard the insoluble fraction.
16. The process of any of claims 12 to 15, wherein said group II-like capsular polysaccharide is eluted with 300 mM NaCl in TrisHCl 20 mM, pH 7.5, 25% propanol-1.
17. The use of any of claims 1 to 3, or the composition of claim 4 or 5, wherein said soluble group II-like capsular polysaccharide is obtained through a process according to any of claims 6 to 16.
18. The composition of any of claims 4, 5 and 17, which is formulated for preventive or therapeutic administration to a subject in need thereof.
19. An anti-biofilm coating, **characterized in that** it comprises a group II-like capsular polysaccharide from a bacterial strain.
20. The anti-biofilm coating of claim 19, **characterized in that** said group II-like capsular polysaccharide is from a bacterial strain selected amongst *Escherichia coli*, *Hemophilus influenzae* and *Neisseria meningitidis*.
21. The anti-biofilm coating of claim 19 or claim 20, **characterized in that** it has been obtained by application of a composition of any one of claims 4, 5 and 17.
22. A medical or industrial device, **characterized in that** it is at least partly coated with an anti-biofilm coating according to any of claims 19, 20 and 21.

Patentansprüche

1. Verwendung eines löslichen Gruppe II-ähnlichen Kapselpolysaccharids aus einem Bakterienstamm für die Herstellung einer Zusammensetzung, welche eine bakterielle Adhäsion und/oder die Entwicklung eines bakteriellen Biofilms verhindert oder inhibiert.
2. Die Verwendung nach Anspruch 1, wobei das lösliche Gruppe II-ähnliche Kapselpolysaccharid enthalten ist in dem Überstand aus einer Bakterienkultur, ausgewählt aus *Escherichia coli*, *Hemophilus influenzae* und *Neisseria meningitidis*.
3. Die Verwendung nach Anspruch 1 oder Anspruch 2, wobei das lösliche Gruppe II-ähnliche Kapselpolysaccharid

erhalten wird als eine gereinigte Fraktion.

4. Eine Zusammensetzung zum Inhibieren der bakteriellen Adhäsion und/oder einer bakteriellen Biofilmentwicklung, **dadurch gekennzeichnet, dass** sie ein lösliches Gruppe II-ähnliches Kapselpolysaccharid aus einem Bakterienstamm umfasst.
5. Die Zusammensetzung nach Anspruch 4, welche eine gereinigte Fraktion aus dem Überstand einer Bakterienkultur, ausgewählt aus *E. coli*, *H. influenzae* und *N. meningitidis*, umfasst.
6. Ein Verfahren zum Reinigen eines Gruppe II-ähnlichen Kapsel-Anti-Biofilm-Polysaccharids aus einem Bakterienstamm, welcher die folgenden Schritte umfasst:
 - (i) Trennen des Überstands einer Kultur aus einem Bakterienstamm, welcher eine Gruppe II-ähnliche Kapsel aus den Bakterienzellen bildet,
 - (ii) Präzipitieren des Polysaccharids, welches in dem erhaltenen Überstand vorliegt, und
 - (iii) gegebenenfalls Resuspendieren des Niederschlags.
7. Das Verfahren nach Anspruch 6, wobei der Bakterienstamm, der eine Gruppe II-ähnliche Kapsel bildet, ausgewählt wird aus *E. coli*, *H. influenzae* und *N. meningitidis*.
8. Das Verfahren nach Anspruch 6 oder Anspruch 7, wobei der Bakterienstamm ein uropathogener *E. coli* ist.
9. Das Verfahren nach irgendeinem der Ansprüche 6 bis 8, wobei die Trennung in Schritt (i) durchgeführt wird durch Filtersterilisation und/oder durch Zentrifugation der Kultur.
10. Das Verfahren nach irgendeinem der Ansprüche 6 bis 9, wobei die Präzipitation in Schritt (ii) durchgeführt wird mit drei Volumina an Ethanol auf ein Volumen Überstand.
11. Das Verfahren nach irgendeinem der Ansprüche 6 bis 10, wobei das Präzipitat, welches in Schritt (ii) erhalten wird, in Wasser resuspendiert wird, gegen deionisiertes Wasser dialysiert wird und dann vor Schritt (iii) lyophilisiert wird.
12. Das Verfahren nach irgendeinem der Ansprüche 6 bis 11, ferner umfassend einen zusätzlichen Schritt (iv) des Reinigens durch Ionenaustauschchromatografie.
13. Das Verfahren nach Anspruch 12, wobei Schritt (iv) durchgeführt wird unter Verwendung einer DEAE-Sepharose-säule.
14. Das Verfahren nach Anspruch 12 oder Anspruch 13, wobei die Resuspendierung in Schritt (iii) durchgeführt wird in TrisHCl 20 mM, pH 7,5, mit 25 % Propanol-1 und die Säule, die in Schritt (iv) verwendet wird, mit demselben Puffer äquilibriert wird.
15. Das Verfahren nach irgendeinem der Ansprüche 12 bis 14, wobei ein Zentrifugationsschritt durchgeführt wird zwischen dem Schritt (iii) und dem Schritt (iv), um die unlösliche Fraktion zu verwerfen.
16. Das Verfahren nach irgendeinem der Ansprüche 12 bis 15, wobei das Gruppe II-ähnliche Kapselpolysaccharid mit 300 mM NaCl in TrisHCl 20 mM, pH 7,5, 25 % Propanol-1 eluiert wird.
17. Die Verwendung nach irgendeinem der Ansprüche 1 bis 3 oder die Zusammensetzung nach Anspruch 4 oder 5, wobei das lösliche Gruppe II-ähnliche Kapselpolysaccharid erhalten wird durch ein Verfahren gemäß irgendeinem der Ansprüche 6 bis 16.
18. Die Zusammensetzung nach irgendeinem der Ansprüche 4, 5 und 17, welche formuliert ist zur vorbeugenden oder therapeutischen Anwendung bei einem Probanden, welcher es benötigt.
19. Eine Anti-Biofilmbeschichtung, **dadurch gekennzeichnet, dass** sie ein Gruppe II-ähnliches Kapselpolysaccharid aus einem Bakterienstamm umfasst.
20. Die Anti-Biofilmbeschichtung gemäß Anspruch 19, **dadurch gekennzeichnet, dass** das Gruppe II-ähnliche Kap-

selpolysaccharid aus einem Bakterienstamm stammt, der ausgewählt wird aus *Escherichia coli*, *Hemophilus influenzae* und *Neisseria meningitidis*.

21. Die Anti-Biofilmbeschichtung nach Anspruch 19 oder 20, **dadurch gekennzeichnet, dass** sie erhalten wird durch Anwenden einer Zusammensetzung aus irgendeinem der Ansprüche 4, 5 und 17.

22. Eine medizinische oder industrielle Vorrichtung, **dadurch gekennzeichnet, dass** sie wenigstens teilweise mit einer Anti-Biofilmbeschichtung gemäß einem der Ansprüche 19, 20 und 21 beschichtet ist.

Revendications

1. Utilisation d'un polysaccharide capsulaire de type groupe II soluble provenant d'une souche bactérienne, pour la préparation d'une composition qui prévient ou inhibe l'adhérence bactérienne et/ou le développement d'un biofilm bactérien.

2. Utilisation selon la revendication 1, où ledit polysaccharide capsulaire de type groupe II soluble est obtenu dans le surnageant d'une culture de bactéries choisies parmi *Escherichia coli*, *Haemophilus influenzae* et *Neisseria meningitidis*.

3. Utilisation selon la revendication 1 ou la revendication 2, où ledit polysaccharide capsulaire de type groupe II soluble est obtenu sous la forme d'une fraction purifiée.

4. Composition destinée à l'inhibition de l'adhérence bactérienne et/ou du développement d'un biofilm bactérien, **caractérisée en ce qu'elle** comprend un polysaccharide capsulaire de type groupe II soluble provenant d'une souche bactérienne.

5. Composition selon la revendication 4, qui comprend une fraction purifiée du surnageant d'une culture de bactéries choisies parmi *E. coli*, *H. influenzae* et *N. meningitidis*.

6. Procédé de purification d'un polysaccharide capsulaire de type groupe II anti-biofilm provenant d'une souche bactérienne, comprenant les étapes suivantes :

- (i) la séparation du surnageant d'une culture d'une souche bactérienne exprimant une capsule de type groupe II à partir des cellules bactériennes,
- (ii) la précipitation des polysaccharides présents dans le surnageant obtenu, et
- (iii) éventuellement la remise en suspension du précipité.

7. Procédé selon la revendication 6, dans lequel ladite souche bactérienne exprimant une capsule de type groupe II est choisie parmi *E. coli*, *H. influenzae* et *N. meningitidis*.

8. Procédé selon la revendication 6 ou la revendication 7, dans lequel ladite souche bactérienne est un *E. coli* uropathogène.

9. Procédé selon l'une quelconque des revendications 6 à 8, dans lequel la séparation dans l'étape (i) est réalisée par stérilisation sur filtre et/ou par centrifugation de la culture.

10. Procédé selon l'une quelconque des revendications 6 à 9, dans lequel la précipitation dans l'étape (ii) est réalisée avec trois volumes d'éthanol pour un volume de surnageant.

11. Procédé selon l'une quelconque des revendications 6 à 10, dans lequel le précipité obtenu dans l'étape (ii) est remis en suspension dans de l'eau, dialysé contre de l'eau désionisée et ensuite lyophilisé avant l'étape (iii).

12. Procédé selon l'une quelconque des revendications 6 à 11, comprenant en outre une étape (iv) supplémentaire de purification par chromatographie par échange d'ions.

13. Procédé selon la revendication 12, dans lequel l'étape (iv) est réalisée en utilisant une colonne DEAE-Sepharose.

14. Procédé selon la revendication 12 ou la revendication 13, dans lequel la remise en suspension dans l'étape (iii) est réalisée dans du Tris-HCl 20 mM, pH 7,5, avec 25 % de propan-1-ol, et la colonne utilisée dans l'étape (iv) est équilibrée avec le même tampon.

5 15. Procédé selon l'une quelconque des revendications 12 à 14, dans lequel une étape de centrifugation est réalisée entre l'étape (iii) et l'étape (iv) pour éliminer la fraction insoluble.

10 16. Procédé selon l'une quelconque des revendications 12 à 15, dans lequel ledit polysaccharide capsulaire de type groupe II est élué avec 300 mM de NaCl dans du Tris-HCl 20 mM, pH 7,5, 25 % de propan-1-ol.

17. Utilisation selon l'une quelconque des revendications 1 à 3, ou composition selon la revendication 4 ou 5, où ledit polysaccharide capsulaire de type groupe II soluble est obtenu par l'intermédiaire d'un procédé selon l'une quelconque des revendications 6 à 16.

15 18. Composition selon l'une quelconque des revendications 4, 5 et 17, qui est formulée pour une administration préventive ou thérapeutique à un sujet en ayant besoin.

20 19. Revêtement anti-biofilm, **caractérisé en ce qu'il** comprend un polysaccharide capsulaire de type groupe II provenant d'une souche bactérienne.

20 20. Revêtement anti-biofilm selon la revendication 19, **caractérisé en ce que** ledit polysaccharide capsulaire de type groupe II provient d'une souche bactérienne choisie parmi *Escherichia coli*, *Haemophilus influenzae* et *Neisseria meningitidis*.

25 21. Revêtement anti-biofilm selon la revendication 19 ou la revendication 20, **caractérisé en ce qu'il** a été obtenu par application d'une composition selon l'une quelconque des revendications 4, 5 et 17.

30 22. Dispositif médical ou industriel, **caractérisé en ce qu'il** est au moins partiellement revêtu d'un revêtement anti-biofilm selon l'une quelconque des revendications 19, 20 et 21.

35

40

45

50

55




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Non-patent literature cited in the description

- **Bahrani-Mougeot, F. K. ; Buckles, E. L. ; Lockatell, C. V. ; Hebel, J. R. ; Johnson, D. E. ; Tang, C. M. ; Donnenberg, M. S.** Type 1 fimbriae and extracellular polysaccharides are preeminent uropathogenic *Escherichia coli* virulence determinants in the murine urinary tract. *Mol Microbiol*, 2002, vol. 45, 1079-1093 [0056]
- **Beloin, C. ; Da Re, S. ; Ghigo, J. M.** *Escherichia coli* and *Salmonella* Cellular and Molecular Biology. ASM Press, 2005 [0056]
- **Beloin, C. ; Michaelis, K. ; Lindner, K. ; Landini, P. ; Hacker, J. ; Ghigo, J. M. ; Dobrindt, U.** The Transcriptional Antiterminator RfaH Represses Biofilm Formation in *Escherichia coli*. *J Bacteriol*, 2006, vol. 188, 1316-1331 [0056]
- **Boyd, E. F. ; Hartl, D. L.** Chromosomal regions specific to pathogenic isolates of *Escherichia coli* have a phylogenetically clustered distribution. *J Bacteriol*, 1998, vol. 180, 1159-1165 [0056]
- **Caruso, F. ; Lichtenfeld, H. ; Donath, E. ; Möhwald, H.** Investigation of electrostatic interactions in polyelectrolyte multilayer films: binding of anionic fluorescent probes to layers assembled onto colloids. *Macromolecules*, 1999, vol. 32, 2317-2328 [0056]
- **Christensen, B. B. ; Sternberg, C. ; Andersen, J. B. ; Palmer, R. J., Jr. ; Nielsen, A. T. ; Givskov, M. ; Molin, S.** Molecular tools for study of biofilm physiology. *Methods Enzymol*, 1999, vol. 310, 20-42 [0056]
- **Cross, A. S. ; Kim, K. S. ; Wright, D. C. ; Sadoff, J. C. ; Gernski, P.** Role of lipopolysaccharide and capsule in the serum resistance of bacteremic strains of *Escherichia coli*. *J Infect Dis*, 1986, vol. 154, 497-503 [0056]
- **Cucarella, C. ; Solano, C. ; Valle, J. ; Amorena, B. ; Lasa, I. I. ; Penades, J. R.** Bap, a *Staphylococcus aureus* Surface Protein Involved in Biofilm Formation. *J Bacteriol*, 2001, vol. 183, 2888-2896 [0056]
- **Da Re, S. ; Ghigo, J. M.** A CsgD-independent pathway for cellulose production and biofilm formation in *Escherichia coli*. *J Bacteriol*, 2006, vol. 188 [0056]
- **de Gennes, P. G.** Polymers at an interface: a simplified view. *Adv Colloid Interface Sci*, 1987, vol. 27, 189-209 [0056]
- **Decher, G.** Fuzzy Nanoassemblies: Toward Layered Polymeric Multicomposites. *Science*, 1997, vol. 277, 1232-1237 [0056]
- **Deghmane, A. E. ; Giorgini, D. ; Larribe, M. ; Alonso, J. M. ; Taha, M. K.** Down-regulation of pili and capsule of *Neisseria meningitidis* upon contact with epithelial cells is mediated by CrgA regulatory protein. *Mol Microbiol*, 2002, vol. 43, 1555-1564 [0056]
- **d'Enfert, C. ; Fontaine, T.** Molecular characterization of the *Aspergillus nidulans* treA gene encoding an acid trehalase required for growth on trehalose. *Mol Microbiol*, 1997, vol. 24, 203-216 [0056]
- **Dubois, M. ; Gilles, K. A. ; Hamilton, J. K. ; Rebers, P. A. ; Smith, F.** Colorimetric method for determination of sugars and related substances. *Anal Chem*, 1956, vol. 28, 350-356 [0056]
- **Favre-Bonte, S. ; Licht, T. R. ; Forestier, C. ; Krogfelt, K. A.** *Klebsiella pneumoniae* capsule expression is necessary for colonization of large intestines of streptomycin-treated mice. *Infect Immun*, 1999, vol. 67, 6152-6156 [0056]
- **Fontaine, T. ; Simenel, C. ; Dubreucq, G. ; Adam, O. ; Delepierre, M. ; Lemoine, J. ; Vorgias, C. E. ; Diaquin, M. ; Latge, J. P.** Molecular organization of the alkali-insoluble fraction of *aspergillus fumigatus* cell wall. *J Biol Chem*, 2000, vol. 275, 41528 [0056]
- **Galdbart, J. O. ; Allignet, J. ; Tung, H. S. ; Ryden, C. ; El Solh, N.** Screening for *Staphylococcus epidermidis* markers discriminating between skinflora strains and those responsible for infections of joint prostheses. *J Infect Dis*, 2000, vol. 182, 351-355 [0056]
- **Ghigo, J. M.** Natural conjugative plasmids induce bacterial biofilm development. *Nature*, 2001, vol. 412, 442-445 [0056]
- **Hall-Stoodley, L. ; Costerton, J. W. ; Stoodley, P.** Bacterial biofilms: from the natural environment to infectious diseases. *Nat Rev Microbiol*, 2004, vol. 2, 95-108 [0056]
- **Heilmann, C. ; Gerke, C. ; Perdreau-Remington, F. ; Gotz, F.** Characterization of Tn917 insertion mutants of *Staphylococcus epidermidis* affected in biofilm formation. *Infect Immun*, 1996, vol. 64, 277-282 [0056]
- **Jann, K. ; Jann, B. ; Schmidt, M. A. ; Vann, W. F.** Structure of the *Escherichia coli* K2 capsular antigen, a teichoic acid-like polymer. *J Bacteriol*, 1980, vol. 143, 1108-1115 [0056]

- **Johnson, J. R. ; O'Bryan, T. T.** Detection of the *Escherichia coli* group 2 polysaccharide capsule synthesis Gene *kpsM* by a rapid and specific PCR-based assay. *J Clin Microbiol*, 2004, vol. 42, 1773-1776 [0056]
- **Kaijser, B.** Immunology of *Escherichia coli*: K antigen and its relation to urinary-tract infection. *J Infect Dis*, 1973, vol. 127, 670-677 [0056]
- **Kaper, J. B. ; Nataro, J. P. ; Mobley, H. L.** Pathogenic *Escherichia coli*. *Nat Rev Microbiol*, 2004, vol. 2, 123-140 [0056]
- **Leboeuf, D. ; Henry, N.** Molecular bond formation between surfaces: anchoring and shearing effects. *Langmuir*, 2006, vol. 22, 127-133 [0056]
- **Maroncle, N. ; Rich, C. ; Forestier, C.** The role of *Klebsiella pneumoniae* urease in intestinal colonization and resistance to gastrointestinal stress. *Res Microbiol*, 2006, vol. 157, 184-193 [0056]
- **Meier, C. ; Oelschlaeger, T. A. ; Merkert, H. ; Korhonen, T. K. ; Hacker, J.** Ability of *Escherichia coli* isolates that cause meningitis in newborns to invade epithelial and endothelial cells. *Infect Immun*, 1996, vol. 64, 2391-2399 [0056]
- **Mobley, H. L. ; Green, D. M. ; Trifillis, A. L. ; Johnson, D. E. ; Chippendale, G. R. ; Lockatell, C. V. ; Jones, B. D. ; Warren, J. W.** Pyelonephritogenic *Escherichia coli* and killing of cultured human renal proximal tubular epithelial cells: role of hemolysin in some strains. *Infect Immun*, 1990, vol. 58, 1281-1289 [0056]
- **Neu, T. R.** Significance of bacterial surface-active compounds in interaction of bacteria with interfaces. *Microbiol Rev*, 1996, vol. 60, 151-166 [0056]
- **Ochman, H. ; Selander, R. K.** Standard reference strains of *Escherichia coli* from natural populations. *J Bacteriol*, 1984, vol. 157, 690-693 [0056]
- **O'Toole, G. A. ; Kolter, R.** Initiation of biofilm formation in *Pseudomonas fluorescens* WCS365 proceeds via multiple, convergent signalling pathways: a genetic analysis. *Mol Microbiol*, 1998, vol. 28, 449-461 [0056]
- **Pluschke, G. ; Mayden, J. ; Achtman, M. ; Levine, R. P.** Role of the capsule and the O antigen in resistance of O18:K *Escherichia coli* to complement-mediated killing. *Infect Immun*, 1983, vol. 42, 907-913 [0056]
- **Roberts, I. S.** The biochemistry and genetics of capsular polysaccharide production in bacteria. *Annu Rev Microbiol*, 1996, vol. 50, 285-315 [0056]
- **Russo, T. A. ; Sharma, G. ; Weiss, J. ; Brown, C.** The construction and characterization of colanic acid deficient mutants in an extraintestinal isolate of *Escherichia coli* (O4/K54/H5). *Microb Pathog*, 1995, vol. 18, 269-278 [0056]
- **Sandberg, T. ; Kaijser, B. ; Lidin-Janson, G. ; Lincoln, K. ; Orskov, F. ; Orskov, I. ; Stokland, E. ; Svanborg-Eden, C.** Virulence of *Escherichia coli* in relation to host factors in women with symptomatic urinary tract infection. *J Clin Microbiol*, 1988, vol. 26, 1471-1476 [0056]
- **Schachter, B.** Slimy business--the biotechnology of biofilms. *Nat Biotechnol*, 2003, vol. 21, 361-365 [0056]
- **Schembri, M. A. ; Dalsgaard, D. ; Klemm, P.** Capsule shields the function of short bacterial adhesins. *J Bacteriol*, 2004, vol. 186, 1249-1257 [0056]
- **Polysialic acid capsule of *Escherichia coli* K1. Silver, R. P. ; Vimr, E. R.** Molecular Basis of Bacterial Pathogenesis. Academic Press, Inc, 1984, 39-60 [0056]
- **Strauch, K. L. ; Beckwith, J.** An *Escherichia coli* mutation preventing degradation of abnormal periplasmic proteins. *Proc Natl Acad Sci U S A*, 1988, vol. 85, 1576-1580 [0056]
- **Toledo-Arana, A. ; Valle, J. ; Solano, C. ; Arrizubieta, M. J. ; Cucarella, C. ; Lamata, M. ; Amorena, B. ; Leiva, J. ; Penades, J. R. ; Lasa, I.** The Enterococcal Surface Protein, Esp, Is Involved in *Enterococcus faecalis* Biofilm Formation. *Appl Environ Microbiol*, 2001, vol. 67, 4538-4545 [0056]
- **Valle, J. ; Toledo-Arana, A. ; Berasain, C. ; Ghigo, J. M. ; Amorena, B. ; Penades, J. R. ; Lasa, I.** SarA and not sigmaB is essential for biofilm development by *Staphylococcus aureus*. *Mol Microbiol*, 2003, vol. 48, 1075-1087 [0056]
- **Vasseur, P. ; Vallet-Gely, I. ; Soscia, C. ; Genin, S. ; Filloux, A.** The *pel* genes of the *Pseudomonas aeruginosa* PAK strain are involved at early and late stages of biofilm formation. *Microbiology*, 2005, vol. 151, 985-997 [0056]
- **Vidal, O. ; Longin, R. ; Prigent-Combaret, C. ; Dorel, C. ; Hooreman, M. ; Lejeune, P.** Isolation of an *Escherichia coli* K-12 mutant strain able to form biofilms on inert surfaces: involvement of a new *ompR* allele that increases curli expression. *J Bacteriol*, 1998, vol. 180, 2442-2449 [0056]
- **Waters, C. M. ; Bassler, B. L.** Quorum sensing: cell-to-cell communication in bacteria. *Annu Rev Cell Dev Biol*, 2005, vol. 21, 319-346 [0056]
- **Whitfield, C.** Biosynthesis and assembly of capsular polysaccharides in *Escherichia coli*. *Annu Rev Biochem*, 2006, vol. 75, 39-68 [0056]
- **Whitfield, C. ; Roberts, I. S.** Structure, assembly and regulation of expression of capsules in *Escherichia coli*. *Mol Microbiol*, 1999, vol. 31, 1307-1319 [0056]